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1.  Abstract 
 
Two-directional synthesis is an effective strategy employed in the synthesis of 3,5-disubstituted 
pyrrolizidine and indolizidine alkaloids. This thesis reports the use of a two-directional approach 
coupled with a “clip-cycle” methodology to access the pyrrolizidine motif via an asymmetric 
pathway. The method involves clipping a linear protected amino-diene with an α,β-unsaturated 
thioester via a double alkene cross metathesis, followed by an asymmetric intramolecular Michael 
cyclisation catalyzed by a chiral phosphoric acid catalyst ((R)-TRIP). The use of an α,β-unsaturated 
thioester as the Michael acceptor in the intramolecular aza-Michael reaction allowed the chiral 
pyrrolidines to be obtained with high enantioselectivities and yields. Subsequent deprotection and 
cyclisation led to the formation of a meso-pyrrolizidine with a cis-cis configuration.   
 
Scheme 1. Asymmetric “clip-cycle” synthesis 
 
 
Scheme 2. Deprotection-cyclisation to form a 3,5-disubstituted pyrrolizidine 
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8.  Introduction 
8.1.  Pyrrolizidine and Indolizidine Alkaloids 
 
Natural products have become an appealing starting point for the discovery and development of 
new drug molecules. This is mainly due to their structural and chemical diversity and seemingly 
abundant occurrence in Nature, as new natural products are discovered frequently.1 Within many 
of the drugs currently in use today N-heterocycles are the most commonly observed moiety, 
contributing to 59% of U.S. FDA approved pharmaceuticals.2 A good example is the anticancer drugs 
Vincristine and Vinblastine extracted from the Madagascar Periwinkle plant (Figure 1).3 Both 
compounds contain a piperidine (green), an indole (blue), an indoline (purple) and an indolizidine 
(red). Often it is difficult to extract natural products on a large enough scale to meet medical 
demands, and so synthetic routes for pharmaceutically important molecules must be established.  
 
Figure 1. Anticancer drugs Vincristine and Vinblastine 
 
Herein, the focus is on the synthesis of the pyrrolizidine and indolizidine moiety found in many 
naturally occurring alkaloids. Pyrrolizidines have two five-membered rings fused together whereas 
indolizidines have a five-membered ring fused to six-membered ring, with both motifs sharing a 
common nitrogen atom. Pyrrolizidine and indolizidine alkaloids have been isolated from a wide 
range of sources in Nature, from poison dart frogs and ants to plants and trees (Figure 2).4  
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Figure 2. Representative examples of naturally occurring pyrrolizidine and indolizidine alkaloids 
 
Many of these natural products have been shown to exhibit significant biological activity and have 
therefore garnered interest within the pharmaceutical industry as potential lead compounds for 
new drug discovery.5 Mitomycin C, castanospermine and its analogue celgosivir are examples of 
the potential of small molecule pyrrolizidine and indolizidine alkaloids with medicinal properties 
(Figure 3). Mitomycin C has been used to treat a number of cancers due to its antitumor and 
antibiotic activity.6 Castanospermine has been shown to inhibit the dengue virus found in 
mosquitoes,7 whereas celgosivir is a potential treatment for the hepatitis C virus.8 Numerous 
synthetic strategies have been developed for the synthesis of natural and unnatural pyrrolizidine 
and indolizidine alkaloids.9  
 
Figure 3. Pyrrolizidine mitomycin C and indolizidines castanospermine and celgosivir 
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8.2.  Synthesis of 3,5-disubstituted Pyrrolizidine and Indolizidine Alkaloids 
 
As a large number of pyrrolizidine and indolizidine alkaloids have now been isolated from Nature 
and many of them exhibit biological activities of interest to the pharmaceutical industry,10 
numerous methodologies towards the total synthesis of these important alkaloids have been 
developed.9 Herein, we discuss a selection of synthetic approaches employed in the total synthesis 
of 3,5-disubstituted pyrrolizidine and indolizidine alkaloids. 
A common strategy to enantioenriched alkaloids is the use of chiral pool synthesis, which utilizes 
enantiomerically pure starting materials that are cheap and readily available in Nature. Amino 
acids, hydroxy acids, carbohydrates and terpenes are the most frequently used naturally occurring 
molecules for this methodology. The strategy involves carrying forward the structure and inbuilt 
chirality of the starting material to the target molecule.11 The amino acid proline has been shown 
to be an effective chiral synthon in the synthesis of pyrrolizidines and indolizidines.12   
Lhommet et. al. demonstrate the use of (S)-proline for the total synthesis of (-)-indolizidine 195B.13 
The first key step involves an anodic α-methoxylation at the 5 position on the Cbz protected (S)-
proline methyl ester 1 to form 3, which proceeds via iminium ion intermediate 2 (Scheme 3). The 
second key step is the boron trifluoride mediated coupling of pent-4-enyl copper to generate 4, 
which was achieved with a high diastereoselectivity towards the trans diastereomer (96:4). To 
install the butyl functionality located at the 3 position of (-)-indolizidine 195B, compound 4 
underwent chemoselective reduction of the methyl ester using sodium borohydride to give alcohol 
5. At this stage the diastereomers could be separated allowing the trans isomer to be obtained in a 
73% yield. Alcohol 5 was then tosylated to 6 before undergoing homologation by nucleophilic 
displacement of the tosylate group in the presence of excess n-Pr2CuLi to give 7.  This gave the 
desired butyl group at the 2 position of the pyrrolidine whilst the chirality of the stereocenter had 
been retained. Compound 7 was then converted into (-)-indolizidine 195B 9 in two steps. Firstly, 
oxidation of the terminal alkene to form ketone 8 via the Wacker process. Secondly, deprotection 
of the Cbz group via hydrogenolysis using H2 and Pd/C, which led to the intramolecular cyclization 
to form (-)-indolizidine 195B 9 with an 81% yield. Overall, 9 was obtained with a 19% yield over 7 
steps starting from 1.  
   14 
 
 
Scheme 3. Total synthesis of (-)-indolizidine 195B form (S)-proline13 
 
Alternatively, Takahata and co-workers have accomplished the total synthesis of the pyrrolizidine 
alkaloid (+)-xenovenine using D-alanine as a chiral synthon.14 Their synthesis began from N-
alkenylurethane 11 which is readily available from D-alanine 10 (Scheme 4). Again, the chirality of 
11 is carried through the synthesis to the final product and in this case no further manipulations to 
the methyl group were required. The first step involved the intramolecular cyclization of 11 to form 
the organomercury pyrrolidine 12 using mercury acetate. The reaction was found to be 
stereoselective towards the trans diastereomer, as after demecuration of 12 via oxidation gave 
only the trans diastereomer of alcohol 13 with a 75% yield. Primary alcohol 13 then underwent 
oxidation to aldehyde 14 using the Parikh-Doering oxidation method.15 Without purification, 
elongation of aldehyde 14 was achieved via a Horner-Wadsworth-Emmons reaction, generating 
compound 15 in an overall yield of 49% from alcohol 13 with selectivity towards the E-alkene (E:Z / 
8:1). Compound 15 then underwent simultaneous Cbz deprotection and alkene hydrogenation of 
the α,β-unsaturated ketone using H2 with palladium hydroxide as a catalyst. This led to the 
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stereoselective intramolecular cyclization to form (+)-xenovenine 16 with a yield of 58%. Overall, 
16 was obtained with a 21% yield over 5 steps starting from 11.  
 
Scheme 4. Total synthesis of (+)-xenovenine from D-alanine14 
 
Another approach utilized for the synthesis of indolizidines is the application of the [4+2] 
cycloaddition reaction in forming six-membered rings. The intramolecular [4+2] cycloaddition 
reaction has been shown to be a useful method employed in the synthesis of natural products.16 
Watanabe et. al. report the total synthesis of (±)-monomorine using an intramolecular nitroso [4+2] 
cycloaddition reaction as a key step in the reaction sequence (Scheme 5).17 Starting from 
hydroxamic acid 18, obtained in 5 steps from (E)-2-heptenoate 17, the bicyclic oxazine 20 was 
obtained via an in-situ [4+2] cycloaddition (19) after periodate oxidation. Oxazine 20 was isolated 
as a single diastereomer with a good yield of 82%. Here the nitroso group acts as the dienophile in 
the [4+2] cycloaddition reaction. Oxazine 20 is then converted to oxazine 21 by hydrogenation of 
the alkene using H2 with Pd/C as the catalyst. To install the methyl functionality located at the 5 
position of monomorine I, oxazine 21 underwent a Grignard reaction with methyl magnesium 
bromide followed by catalytic hydrogenation to give oxazine 22 as a single isomer with a yield of 
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71%. Reductive cleavage of the N-O bond using zinc dust in aqueous acetic acid led to the 
stereoselective formation of the 2,6-disubstituted piperidine 23, which had the desired cis 
configuration. Piperidine 23 was then Cbz protected with benzyl chloroformate before undergoing 
a Collins oxidation of the secondary alcohol to form the ketone (25). With the ketone functionality 
installed, Cbz deprotection of piperidine 25 using H2 with Pd/C as the catalyst allowed for the 
intramolecular cyclization to form monomorine I 26 racemically, with a yield of 71%. 
 
Scheme 5. Total synthesis of (±)-monomorine I via a [4+2] cycloaddition reaction17 
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Recently, Glorius and co-workers have investigated a more direct route to indolizidines via catalytic 
hydrogenation of substituted indolizines using a chiral ruthenium complex with an N-heterocyclic 
carbene ligand. They have demonstrated the effectiveness of this strategy in the asymmetric 
synthesis of unnatural (-)-monomorine I (Scheme 6).18 The use of chiral ligand 28 with the 
ruthenium complex allowed the hydrogenation of 3-butyl-5-methylindolizine 27 to form compound 
29 in near quantitative yield. The reaction is both regioselective, only the six-membered ring is 
hydrogenated, and stereoselective generating 29 with an enantiomeric excess of 94%. Compound 
29 was then subjected to a second catalytic hydrogenation using H2 and Adams catalyst (platinum 
oxide) to generate monomorine I 30 in near quantitative yield with high diastereoselectivity 
(95:5:2:1 dr). The major product was determined to be the unnatural (-)-monomorine I 30. 
 
Scheme 6. Synthesis of (-)-monomorine I via catalytic hydrogenation18 
 
Another strategy widely employed for the synthesis of pyrrolizidines and indolizidines is the use of 
transition metals to catalyze the intramolecular cyclization reaction to form six-membered or five-
membered N-heterocycles with a high degree of stereoselectivity. This method is particularly useful 
for the stereocontrolled formation of new C-N bonds required for the synthesis of pyrrolizidines 
and indolizidines.9 Livinghouse et. al. have reported a diastereoselective synthesis of (±)-
xenovenine using a scandium complex to catalyze an intramolecular hydroamination cyclization 
(Scheme 7).19 Starting from hydrazone 31, ketone 32 was obtained via a 3 step one-pot reaction 
involving lithiation with LDA followed by alkylation and finally hydrolysis of the hydrazone. Ketone 
32 was then coupled with 5-ethylthiophene-2-boronic acid (33) to form ketone 34, which was 
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obtained as a mixture of Z- and E- isomers (4:1). The cyclization precursor 35 was then acquired via 
reductive amination of 34. The importance of the alkylthiophene substituent becomes apparent 
during the second intramolecular cyclization, it not only activates the alkene allowing the cyclization 
to proceed at a lower temperature and reaction time, but also can be reduced to give the alkyl 
chain present in xenovenine. 
 
Scheme 7. Synthesis of (±)-xenovenine via transition metal catalyzed hydroamination19 
 
Treatment of precursor 35 with the scandium complex 36 in deuterated toluene at 10 °C allowed 
the diastereoselective intramolecular cyclization to form pyrrolidine 37 in a high yield of 95%, with 
the trans-diastereomer as the major product (trans:cis / 49:1). The second cyclization to form 
pyrrolizidine 38 from pyrrolidine 37 was achieved by increasing the reaction temperature from 10 
°C to 60 °C, they also noted that 38 could be obtained directly from 35 by running the reaction from 
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the start at 60 °C. Finally, reduction of the alkylthiophene substituent using Raney® nickel gave 
xenovenine 39 racemically in a 98% yield. Overall, (±)-xenovenine 39 was synthesized with a 44% 
yield in 5 steps starting from hydrazone 31.      
Makabe et. al. have reported an asymmetric synthesis of (+)-monomorine via a diastereoselective 
intramolecular aminopalladation.20 Intramolecular aminopalladation involves the activation of an 
alkene by coordination of a palladium complex, the resulting alkene-palladium complex can then 
undergo nucleophilic attack by the nitrogen to form a heterocycle. This method has been shown to 
be a useful strategy in the synthesis of N-heterocycles in particular pyrrolidines and piperidines.21 
Makabe and coworkers utilize the intramolecular aminopalladation method to form a 2,6-
disubstituted piperidine (41) diastereoselectively, as the key step in the synthesis of (+)-
monomorine I (Scheme 8).  
 
Scheme 8. Asymmetric synthesis of (+)-monomorine I via diastereoselective aminopalladation20 
 
The reaction time was found to be an important factor in achieving the desired stereochemistry of 
the piperidine. When the reaction was run for 30 min piperidine 41 was obtained in a ratio of 67:33 
in favor of the cis-diastereomer with a 49% yield. Whereas, increasing the reaction time to five 
hours allowed the formation of piperidine 41 in a ratio of 98:2 in favor of the cis-diastereomer with 
a 63% yield. They rationalized this result by proposing two transition states which are in equilibrium 
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as shown in Figure 4. Transition state 45 is more stable due to the chelation between the oxygen 
atom of the Boc group and the alcohol group with palladium and the absence of any steric clash 
between these groups shown in transition state 46, which led to the 2,6-trans-piperidine 47. 
Therefore, the favored route is via transition state 45 leading to the formation of the 2,6-cis-
piperidine 41 as the major product. 
 
Figure 4. Preposed transition states for the selective formation of the 2,6-cis-piperidine20 
 
The Boc group on piperidine 41 was then converted to a Cbz group to give piperidine 42. Cross 
metathesis of piperidine 42 with 2-octen-4-one, using Hoveyda-Grubbs Catalyst™ 2nd generation, 
gave the desired chain elongation to form piperidine 43. Simultaneous alkene hydrogenation and 
deprotection of 43 using H2 and Pearlman’s catalyst (Pd(OH)2/C) allowed for the intramolecular 
cyclization to form (+)-monomorine I 44 with a 67% yield. The reason for changing the protecting 
group was because when the Boc protected piperidine was carried forward through the metathesis 
and subsequent alkene reduction, Boc deprotection and intramolecular cyclization a complex 
mixture was formed.  
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8.3.  Two-Directional Synthesis of 3,5-disubstituted Pyrrolizidines and Indolizidines 
 
Two- directional synthesis is a strategy employed for extending the chain of a linear substrate. this 
can be done sequentially, from either end of the substrate, or simultaneously, extending both ends 
via the same reaction (Figure 5). The two-directional strategy has been shown to be a useful 
approach in the synthesis of natural products.22 
 
Figure 5. Two-directional synthesis of a linear substrate 
 
An effective method utilized for the simultaneous two-directional synthesis is the double alkene 
cross metathesis reaction of linear dienes. Investigations into the two-directional cross metathesis 
reaction conducted by Stockman et. al.23 showed that the reaction can be catalyzed by Hoveyda-
Grubbs Catalyst™ 2nd generation at room temperature for a number of different alkenes. Their 
results demonstrated that the corresponding metathesis products could be obtained in high yields 
with selectivity towards the E,E-dienes (Scheme 9).  
 
Scheme 9. Representative example for a two-directional cross metathesis23 
 
The example in Scheme 9 shows the two-directional double alkene cross metathesis between 
symmetrical diene 48 and 6 equivalents of ethyl acrylate, with 5 mol% of Hoveyda-Grubbs Catalyst™ 
2nd generation to generate ketodiester 49 with an excellent yield of 90%. It is worth noting that 
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due to the long reaction time (5 days) they found that adding the catalyst in two portions (2nd 
portion after 24 h) gave the best results. 
Stockman and co-workers have developed a strategy using the two-directional cross metathesis 
method coupled with tandem cyclisation reactions to access 3,5-disubstituted pyrrolizidines and 
reported the first total synthesis of pyrrolizidine alkaloid cis-223B.24 For the initial method towards 
3,5-disubstituted pyrrolizidines they utilized a tandem reaction involving a reductive amination 
followed by a double intramolecular aza-Michael cyclization over three steps in one pot (Scheme 
10).  
 
Scheme 10. Two-directional synthesis coupled with a tandem reductive amination-double 
Michael addition for the synthesis of pyrrolizidines24 
 
The forward synthesis proceeded via a two-directional double alkene cross metathesis between 
symmetrical diene 50 and ethyl acrylate, catalyzed by Hoveyda-Grubbs Catalyst™ 2nd generation. 
This installed the α,β-unsaturated diethyl esters as the Michael acceptors required for the 
intramolecular cyclizations. Although the ketodiester 51 was isolated with a good yield of 66% a 
drawback to the metathesis would be the long reaction time of 9 days. They achieved the reductive 
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amination step by treating ketodiester 51 with ammonia which undergoes nucleophilic attack at 
the ketone to form a hemiaminal followed by elimination of water to form the iminium ion 52. 
These steps are reversible and so titanium ethoxide was added to remove the water and drive the 
reaction towards the iminium ion, which was then reduced with sodium borohydride to form amine 
53. Excess sodium borohydride was removed by reacting it with added acetone before amine 53 
underwent a double intramolecular aza-Michael cyclization catalyzed by glacial acetic acid. This was 
accomplished at a high temperature of 75 °C over a period of 48 hours. The resulting meso-
pyrrolizidine 55 was isolated as a single diastereomer with a cis-cis configuration, with respect to 
the substituents and the bridgehead hydrogen, and in a yield of 71% over the three steps.  
For the total synthesis of pyrrolizidine alkaloid cis-223B they changed the Michael acceptor to an 
enone in order install a diketone functionality to the pyrrolizidine which could then be reduced to 
form the alkaloid. As a result, they surmised that the tandem reductive amination-Michael addition 
method would not be appropriate due to the similar reactivity of the enones and the ketone. 
Instead they chose to use a Boc protected amino-diene (Scheme 11). 
 
Scheme 11. Two-directional synthesis coupled with a tandem acid catalyzed double Michael 
addition for the synthesis of pyrrolizidine 5924 
 
Interestingly, the metathesis between amino-diene 56 and 1-penten-3-one gave the racemic 
pyrrolidine 58 as the major product, demonstrating the increased reactivity of the α,β-unsaturated 
ketone compared to the α,β-unsaturated diethyl ester when used as Michael acceptors. The 
   24 
 
subsequent deprotection and cyclisation of 57 and 58, catalyzed by trifluoroacetic acid, generated 
the meso-pyrrolizidine 59 as a single diastereomer. Pyrrolizidine alkaloid cis-223B 61 was obtained 
from the reduction of the diketone functionality (Scheme 12). This was achieved by converting 
diketone 59 to dithioacetal 60 followed by reduction using Raney® nickel. The total synthesis of 
pyrrolizidine alkaloid cis-223B 61 was accomplished in 7 steps with an overall yield of 43%.  
 
Scheme 12. Reduction of diketone 59 to give pyrrolizidine alkaloid cis-223B 6124 
 
Thus far, the two-directional tandem cyclisation methodology has led to the formation of 
symmetrical (meso) pyrrolizidines. Stockman et. al. has also reported a two-directional approach 
coupled with a tandem triple amination for the total synthesis of unsymmetrical 3,5-disubstituted 
pyrrolizidines.25 The strategy was used for the diastereoselective synthesis of (±)-xenovenine 
(Scheme 13).  The key steps involve the simultaneous formation of Weinreb diamide 64 followed 
by sequential Grignard reactions to install the alkyl chain at one end and a methyl group at the 
other, forming triketone 65. Triple reductive amination of 65 using ammonium acetate and sodium 
borohydride generated the racemic pyrrolizidine xenovenine 39 as a single diastereomer. The total 
synthesis of (±)-xenovenine 39 was achieved in 4 steps with an overall yield of 5%.  
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Scheme 13. Total synthesis of (±)-xenovenine 39 via a triple reductive amination25 
 
Spring et. al. have also demonstrated the use of a two-directional approach to synthesize 3,5-
disubstituted pyrrolizidines and indolizidines.26 For the pyrrolizidines they use the same method as 
Stockman and co-workers used for Boc protected amino-dienes,24 with the difference being the 
choice of the Michael acceptor utilized for the intramolecular double aza-Michael cyclizations. 
Instead of using an α,β-unsaturated ketone they used an α,β-unsaturated diethyl ester (Scheme 
14). Interestingly this led to the formation of two different stereoisomers, the trans-trans meso-
pyrrolizidine 67 and the trans-cis pyrrolizidine 68 with the latter being the major product. Also, the 
cross metathesis was accomplished with a shorter reaction time of 24 hours with an excellent yield 
of 96% and without the formation of the racemic pyrrolidine. 
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Scheme 14. Two-directional synthesis coupled with a tandem acid catalyzed double Michael 
addition for the synthesis of pyrrolizidines26 
 
For the synthesis of the indolizidines, Lewis acids were used to catalyze the intramolecular double 
aza-Michael cyclization to achieve a degree diastereoselectivity, with each reaction generating a 
mixture of diastereomers (Scheme 15). 
 
Scheme 15. Lewis acid catalyzed cyclization for the synthesis of indolizidines26 
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When the unsymmetrical amino-diene 69 was treated with aluminium trichloride the cis-trans 
indolizidine 70a was generated as the major product (55% yield), whereas treating 69 with 
scandium triflate gave the trans-cis indolizidine 71b as the major product (69% yield). In each case 
the cis-cis indolizidine 72a-b was isolated as a minor product, suggesting that the formation of the 
trans-fused indolizidines were more thermodynamically stable than cis-fused indolizidine. 
The work reported by Stockman et. al.24/25 and Spring et. al.26 has demonstrated successfully the 
diastereoselective synthesis of 3,5-disubstituted pyrrolizidines and indolizidines using a two-
directional approach. However, to synthesize 3,5-disubstituted pyrrolizidines and indolizidines 
asymmetrically using this methodology would pose a greater challenge. Introduction of a chiral 
reagent would be needed to catalyze the first intramolecular aza-Michael reaction and control the 
enantioselectivity of the resulting chiral pyrrolidine. The choice of Michael acceptor would also be 
critical as to avoid the formation of the racemic pyrrolidine from the metathesis step and the effect 
it has on the enantioselectivity of the intramolecular cyclization. 
A recent report by Fustero et. al. showed that it is possible to synthesize enantiomerically pure 
quinolizidines asymmetrically using a chiral sulfinyl amine as a chiral auxiliary and a source of 
nitrogen. The asymmetric reaction involves desymmetrization of a linear substrate via an 
intramolecular aza-Michael cyclization.27 The method was utilized for the total synthesis of (-)-
hippodamine and (+)-epi-hippodamine. The symmetrical cyclization precursor was synthesized by 
firstly installing Ellman’s chiral auxiliary via reductive amination of ketodiene 73 followed by a two-
directional double alkene cross metathesis with tert-butyl acrylate to give the diester 74 (Scheme 
16).  
 
Scheme 16. Synthesis of quinolizidine cyclization precursor27 
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The initial intramolecular cyclisation using sodium hydride gave a mixture of the 2,6-cis and 2,6-
trans disubstituted piperidines 76 and 77 (3:1), with the cis as the major product. Although the two 
diastereomers could be separated by flash column chromatography, this was not necessary as 
further cyclisation of both diastereomers led to the enantiomerically pure quinolizidine 78 (Scheme 
17). Further manipulations of quinolizidine 78 over 3 steps gave access to a mixture of (-)-
hippodamine and (+)-epi-hippodamine.27  
 
Scheme 17. Asymmetric synthesis of quinolizidine 7827 
 
The importance of the selectivity from the first intramolecular cyclization was not the cis or trans 
stereochemistry, but the fact that both diastereomers shared the same stereochemistry at the 2 
position on the piperidine ring and the stereochemistry at the 6 position did not affect the second 
intramolecular cyclisation. The stereoselectivity of the first intramolecular cyclization was 
rationalized by two proposed transition states which showed si face attack of the nitrogen 
nucleophile and the importance of the sulfinyl auxiliary in directing the stereochemistry (Scheme 
18). The major cis product arises from the bulky tert-butyl group (R) being in the equatorial position.  
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Scheme 18. Proposed transition states for the formation of piperidines 76 and 7727 
 
An alternative method for the synthesis of N-heterocycles via an asymmetric intramolecular aza-
Michael reaction is the use of chiral Brønsted acid catalysts to induce enantioselectivity. Nagorny 
et. al. reported an enantioselective synthesis of functionalized chiral piperidines using an α,β-
unsaturated dimethyl acetal, as the Michael acceptor, and a chiral phosphoric acid (CPA) to catalyze 
the intramolecular aza-Michael  cyclization (Scheme 19).28    
 
Scheme 19. General scheme for the CPA catalyzed synthesis of chiral piperidines28 
 
The enantioselectivity of the resulting chiral piperidines was found to be highly dependent upon 
the polarity of the solvent, the temperature and the catalyst loading. Nonpolar solvents and low 
temperatures gave the best selectivity and yields. Using carbon tetrachloride as the solvent at -20 
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°C with a catalyst loading of 15 mol% were found to be the optimal conditions for these reactions. 
The procedure was found to be tolerant of substitution at the 4 and 5 positions on the piperidine 
ring (79d-g) and changes to the protecting group (79a-b), generating high yields and ees (Figure 6). 
 
Figure 6. Representative examples for the CPA catalyzed synthesis of chiral piperidines28 
 
Interestingly, increasing the reaction time led to enantioenrichment in all cases except for 
substitution at the 6 position (79c), which led to an increase in yield but a decrease in 
enantioselectivity. The enantioenrichment was assumed to arise from a CPA catalyzed reaction 
between the minor enantiomer and methanol (a by-product of the reaction) leading to the 
formation of an acetal (80). This was demonstrated by subjecting racemic 79a to the optimized 
reaction conditions (Scheme 20). Chiral piperidine 79a was recovered with an increase in 
enantiomeric excess (53% ee). 
 
Scheme 20. Enantioenrichment of racemic 79a28 
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DFT computational analysis determined that the cyclisation proceeds via a two-step mechanism 
involving the formation of a mixed chiral phosphate acetal first which then undergoes a concerted 
asynchronous SN2’-like mechanism to yield the chiral piperidines.28 Although high yields and 
enantioselectivities were achieved, the method is not without its disadvantages such as the use of 
undesirable reaction conditions (-20 °C) and the high toxicity of carbon tetrachloride. 
 
8.4.  Brønsted Acid Catalyzed Synthesis of Chiral Pyrrolidines 
 
To investigate the potential of chiral phosphoric acid catalysts (CPAs) for the asymmetric synthesis 
of N-heterocycles, Clarke et. al. have developed an asymmetric “clip-cycle” strategy for the 
synthesis of 2,2- and 3,3-disubstituted pyrrolidines and spiropyrrolidines.29 The “clip-cycle” 
methodology involves clipping a Cbz-protected amine with an α,β-unsaturated thioester via an 
alkene cross metathesis catalyzed by Hoveyda-Grubbs Catalyst™ 2nd generation. This is followed 
by an asymmetric intramolecular aza-Michael cyclisation, catalyzed by a CPA, to generate chiral 
pyrrolidines in high yields and ees (Scheme 21).  
 
Scheme 21. General scheme for the “clip-cycle” synthesis of chiral pyrrolidines29 
 
Selection of the α,β-unsaturated thioester as the Michael acceptor was critical for achieving high 
yields and enantioselectivities. Alternative Michael acceptors were tested for their suitability 
(Scheme 22). Cbz-protected amine 81 was clipped separately with an α,β-unsaturated ketone, an 
α,β-unsaturated oxoester and an α,β-unsaturated thioester before being cyclized with the CPA (R)-
TRIP. The α,β-unsaturated ketone was found to be far too reactive producing the corresponding 
racemic 3,3-disubstituted pyrrolidine 82 directly from the cross metathesis. The α,β-unsaturated 
oxoester gave the metathesis product 83 in a high yield (86%) but upon cyclization only generated 
the 3,3-disubstituted  pyrrolidine 84 with a yield of 20%, despite having a good enantiomeric excess 
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of 90%. However, the α,β-unsaturated thioester gave a good balance between reactivity and 
selectivity generating the metathesis product 85 with a yield of 75% and the 3,3-disubstituted  
pyrrolidine 86 with a yield of 83% and an enantiomeric excess of 96%. 
 
Scheme 22. Comparison of Michael acceptors for the “clip-cycle” synthesis of chiral pyrrolidines29 
 
The optimal conditions utilized to achieve high yields and ees for the chiral pyrrolidines from the 
asymmetric cyclisation were the result of extensive screening within the Clarke group.30 The 
solvent, temperature, reaction time and CPA catalyst were all investigated using cyclisation 
precursor 87 to form the 2,2-dimethyl substituted pyrrolidine 88 (Table 1 and Figure 7). 
  













1 (R)-TRIP Cyclohexane 80 24 77 92 
2 (R)-TRIP Cyclohexane 50 24 38 90 
3 (R)-TRIP Cyclohexane 50 48 46 94 
4 (R)-TRIP Toluene 50 24 18 92 
5 (R)-TRIP 1,2-DCE 50 24 12 90 
6 (R)-TiPSY Cyclohexane 80 24 22 58 
7 (R)-phen-cat Cyclohexane 80 24 21 46 
8 (R)-anth-cat Cyclohexane 80 24 99 62 
 
Table 1. Reaction conditions screened for the cyclization of 8730 
 
The change in temperature resulted in a dramatic effect on the yield but only a minor effect on the 
ee. Using (R)-TRIP 89 at 80 °C gave a 77% yield whereas running the same reaction at 50 °C gave a 
38% yield (entries 1 and 2). Increasing the reaction time did not result in a significant change in 
either yield or ee when the reaction was run at 50 °C for 24 hours and 48 hours (entries 2 and 3). 
Entries 2, 4 and 5 show that the CPA catalyzed reaction favored non-polar solvents with 
cyclohexane generating the highest yield (38%) compared to toluene (18%) and 1,2-DCE (12%). 
Interestingly the solvent had little effect on the enantioselectivity. However, changing the CPA had 
an effect on both the yields and ees. For (R)-TiPSY 90 and (R)-phen-cat 91 a substantial drop in both 
yield and ee was observed when compared to (R)-TRIP 89 (entries 1, 6 and 7). Whereas, (R)-anth-
cat 92 showed a significant increase in yield but a decrease in ee when compared to (R)-TRIP 89 
(entries 1 and 8). Overall, it was determined that using (R)-TRIP 89 in cyclohexane at 80 °C for 24 
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hours are the optimal reaction conditions for the synthesis of chiral pyrrolidines using the “clip-
cycle” methodology (entry 1, highlighted blue).  
 
Figure 7. Chiral phosphoric acids tested for the asymmetric cyclization 
 
Applying the optimized conditions in the “clip-cycle” methodology allowed chiral pyrrolidines and 
spiropyrrolidines to be synthesized with good yields and high enantioselectivities which was 
demonstrated for a range of substitutions at the 2 and 3 positions on the pyrrolidine ring (Figure 
8).29 For the synthesis of unsubstituted chiral pyrrolidine 93 (R)-TiPSY 90 was used as the catalyst 
to give the highest ee. The methodology could also be used as an effective strategy for the total 
synthesis of natural products. Pyrrolidine alkaloids (R)-bgugaine 96 and (R)-irnidine 97 were 
synthesized enantioselectively in 6 steps with overall yields of 33% and 18% respectively.31 
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Figure 8. Representative examples of chiral pyrrolidines synthesized using the “clip-cycle” 
methodolgy29/31 
 
The absolute stereochemistry of the CPA catalyzed cyclisation was determined by converting the 
unsubstituted chiral pyrrolidine 93 to a methyl ester via transesterification using silver triflate in 
methanol (Scheme 23).32 As there was no erosion of the ee from the functional group 
transformation, comparison of the optical rotation of 98 with that of the same compound reported 
in the literature confirmed the stereochemistry to be (S) for the major enantiomer.33 
 
Scheme 23. Transesterification of 93 to form the methyl ester30 
 
DFT computation analysis of the CPA catalyzed cyclization has been conducted within the Clarke 
group.29 The results showed that the CPA acts as a proton shuttle and proceeds via an aminoenol 
which tautomerizes to give the cyclized product. The intermediate aminoenol can adopt either an 
S,E configuration or an R,Z configuration. As shown in Figure 9, the S,E pathway is lower in energy 
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than the R,Z pathway and therefore the favored route for the cyclisation. This was attributed to the 
steric effect of the thioester α-proton which points inward, towards the catalyst pocket, for the R,Z 
pathway and outwards for the  S,E pathway. Overall, the CPA catalyzed cyclization was determined 
to be the rate- and stereochemistry-determining step.   
 
Figure 9. Computational analysis for the asymmetric cyclisation29 
 
8.5.  Background Work 
 
Encouraged by the high enantioselectivities achieved for the synthesis of 2,2- and 3,3-disubstituted 
pyrrolidines and spiropyrrolidines, work has been done within the Clarke group to adapt the “clip 
cycle” methodology for the synthesis of bicyclic N-heterocycles.30/34 The strategy involves the CPA 
catalyzed desymmetrization of an achiral symmetrical precursor to form a chiral unsymmetrical 
product, which could then undergo further cyclisation to form a bicyclic heterocycle. The initial 
approach for the synthesis of the desymmetrization precursor is outlined below (Scheme 24). The 
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synthesis began by treating ethyl formate 99 with 4-butenyl magnesium bromide (Grignard 
reagent) to give the secondary alcohol 100 in a near quantitative yield of 99%. Alcohol 100 was then 
converted to amino-diene 101 over 2 steps in one pot. The procedure involves treating 100 with 
methanesulfonyl chloride (MsCl) to form an alkyl mesylate, which then undergoes nucleophilic 
attack from ammonia to generate amine 101 and mesylate (excellent leaving group). Amine 101 
was isolated in a very low yield of 12%.  Benzyl chloroformate was then used to Cbz protect 101 
before undergoing a two-directional double alkene cross-metathesis with an α,β-unsaturated p-
tolyl thioester, to give the desymmetrization precursor 103 with a 77% yield.  
 
Scheme 24. Synthesis of the desymmetrization precursor30/34 
 
The optimized conditions used for the cross metathesis were previously developed in the Clarke 
group for the synthesis of 2,2- and 3,3-disubstituted pyrrolidines and spiropyrrolidines.30 Hoveyda-
Grubbs Catalyst™ 2nd generation was used to catalyze the reaction in the presence of a copper 
iodide co-catalyst. Studies conducted by Lipshultz et. al. have demonstrated the importance of the 
addition of copper iodide in cross metathesis reactions when using acrylates.35 The addition of 
copper iodide allowed the Hoveyda-Grubbs Catalyst to be used in catalytic quantities (10 mol%) 
and also aided in increasing the rate of the reaction.36 This was attributed to the ability of the iodine 
ion to stabilize the catalyst, as well as the ability of copper(I) to scavenge the phosphine ligand. 
Precursor 103 was then cyclized using the optimized conditions, (R)-TRIP (20 mol%) in cyclohexane 
at 80 °C for 24 hours (Scheme 25). The 2,5-disubstituted pyrrolidine 104 was obtained as a mixture 
of diastereomers (92:8) with a yield of 77% and the major diastereomer was determined to have 
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an enantiomeric excess of 86%. As the same asymmetric cyclisation conditions had been used for 
the synthesis of 2,2- and 3,3-disubstituted pyrrolidines and spiropyrrolidines, the stereochemistry 
was assigned as the (S) configuration at the 2 position for the major diastereomer.   
 
Scheme 25. Asymmetric cyclisation of 103 using (R)-TRIP30 
 
Determination of the stereochemistry at the 5 position and to ascertain whether or not the major 
diastereomer of pyrrolidine 104 has a cis or trans configuration has yet to be accomplished. 
However, a literature comparison has been done between a 2,5-disubstituted pyrrolidine 
previously synthesized in the Clarke group37 (using the “clip-cycle” methodology) and a similar 
compound reported by Farwick et. al.38 (Figure 10). Pyrrolidine 106 reported in the literature was 
Boc protected and was determined to have a trans configuration, whereas pyrrolidine 105 
synthesized in the Clarke group was Cbz protected. The process involved synthesizing the Cbz 
protected pyrrolidine 105 using the procedure reported by Farwick and co-workers and comparing 
the 1H NMR data to the Boc protected pyrrolidine 106. The 1H NMR data was found to be consistent 
and so the protecting group did not affect the stereochemistry of the chiral pyrrolidine being 
formed in the reaction. Comparison of the 1H NMR data of both Cbz-pyrrolidines (synthesized using 
“clip-cycle” methodology and the Farwick procedure) was also consistent suggesting that 
pyrrolidine 105 has a trans configuration. Although this does not confirm the absolute 
stereochemistry of pyrrolidine 104, we can surmise that the trans configuration forms 
preferentially from the cyclization using the “clip-cycle” methodology. Therefore, the 
stereochemistry for pyrrolidine 104 can be assigned as shown in Scheme 25 with a degree of 
confidence, however definitive proof would need to be obtained through X-ray crystallography. 
 
Figure 10. Chiral pyrrolidines used for determining the cis or trans stereochemistry 
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8.6.  Aim and Scope of the Project 
 
The aim of the project is to continue working towards synthesizing bicyclic heterocycles via a two-
directional approach utilizing the “clip-cycle” methodology developed within the Clarke group. 
Work within the group has shown that 2,5-disubstituted pyrrolidines can be generated with high 
yields and enantioselectivities30/37 and the potential for further cyclisation to the bicyclic 
heterocycles has yet to be investigated. The focus will be on the synthesis of the pyrrolizidine and 
indolizidine motifs via an asymmetric pathway using linear substrates and determining the absolute 
stereochemistry of resulting 3,5-disubstituted pyrrolizidines and indolizidines (Scheme 26).    
 
Scheme 26. Deprotection-cyclisation to form pyrrolizidines and indolizidines 
 
Attempts will also be made to selectively functionalize the saturated thioester formed from the 
initial asymmetric cyclisation to the pyrrolidine, to enable access to naturally occurring 3,5-
disubstituted pyrrolizidine and indolizidine alkaloids asymmetrically (Figure 11).    
 
Figure 11. Potential pyrrolizidine and Indolizidine alkaloid targets 
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9.  Results and Discussion 
9.1.  Retrosynthetic Analysis of the Pyrrolizidine Precursor 
 
Retrosynthetic analysis of the cyclization precursor demonstrates a synthetic route via 
commercially available starting materials (Scheme 27). Cyclisation precursors 103 and 107 can be 
synthesized from the protected amines 102 and 56 using thioacrylate 108 via a two-directional 
double alkene cross metathesis reaction. Acylation of thiol 109 with acryloyl chloride 110 can be 
used to prepare thioacrylate 108. Functional group interconversion of secondary alcohol 100 to the 
primary amine 101 can be achieved via a Mitsunobu reaction, the amine can then be Cbz or Boc-
protected. Secondary alcohol 100 can be easily obtained from a Grignard reaction between two 
equivalents of metalated 4-bromobutene 111 and ethyl formate 99. 
 
Scheme 27. Retrosynthetic analysis of cyclisation precursors 103 and 107 
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9.2.  Synthesis of Pyrrolizidine Precursors 
 
The forward synthesis began with the synthesis of the α,β-unsaturated p-tolyl thioester 108 using 
a previously published procedure (Scheme 28).39 The method involved treating p-thiocresol 109 
with an aqueous solution of NaOH to form the sodium salt 112, this was done in the presence of 
sodium borohydride to prevent the formation of disulfides. The sodium salt then underwent 
acylation after being added to a solution of acryloyl chloride and BHT in cyclohexane, which 
generated thioester 108 in a moderate yield of 53%. BHT was added at this stage and during 
purification to prevent radical polymerization. Although the product was contaminated with BHT, 
it was found that it did not interfere with cross-metathesis reactions and the yield was easily 
calculated from the 1H NMR spectrum. 
 
Scheme 28. Synthesis of α,β-unsaturated p-tolyl thioester 108 
 
The next step was to synthesize the symmetrical amino-diene 101 via a 3-step synthesis based on 
a literature procedure (Scheme 29).40 
  
Scheme 29. Literature procedure for the synthesis of amine 10140 
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This procedure was utilized in preference to the method already employed by the Clarke group, as 
previously discussed (Scheme 24).34 This was due to the poor yield of amine 101 (12%) and the need 
to increase the available material for subsequent reactions. The forward synthesis began with a 
Grignard reaction between 4-butenyl magnesium bromide and ethyl formate 99 to generate 
alcohol 100 in a good yield of 86% (Scheme 30).   
 
Scheme 30. Synthesis of pyrrolizidine cyclisation precursors 103 and 107 
 
Converting alcohol 100 to the amine salt 114 was achieved through a Mitsunobu reaction. The 
Mitsunobu reaction is more commonly used for the conversion of primary and secondary alcohols 
to esters (esterification), with inversion of the stereochemistry via a SN2-mechanism, which can 
then be hydrolyzed to give the inverted alcohol.41 Here, the Mitsunobu method is utilized to 
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generate a tertiary amine from a secondary alcohol using a phthalimide as the N-nucleophile. The 
reaction proceeds by activation of the alcohol 100 and phthalimide by a zwitterionic intermediate 
formed from diethyl azodicarboxylate (DEAD) and triphenylphosphine. The resulting nucleophilic 
substitution generated N-alkyl phthalimide 113 in a moderate yield of 58% and triphenylphosphine 
oxide as a byproduct.  
N-Alkyl phthalimide 113 then underwent hydrazinolysis with hydrazine hydrate, using the Ing-
Manske procedure,42 to generate the free amine. Due to the high volatility of the amine, a 2M HCl 
aqueous solution was used during workup to form the amine salt 114 which was isolated with an 
excellent yield of 90%. Amine salt 114 was then either Cbz-protected43 with benzyl chloroformate 
or Boc-protected44 with di-tert-butyl dicarbonate. This allowed for the investigation into the effect 
of the protecting group on the Brønsted acid catalyzed cyclisation reactions. The Cbz-protected 
amine 102 was isolated with a good yield of 81% whereas the Boc-protected amine 56 was isolated 
with a lower yield of 68%.  
The final step involved “clipping” of the protected amines 102 and 56 with p-tolyl thioester 108 via 
a two-directional double alkene cross-metathesis reaction using the optimized conditions 
developed in the Clarke group.30 The double cross-metathesis was performed using Hoveyda-
Grubbs Catalyst™ 2nd generation (10 mol%) and CuI as a co-catalyst, with 6 equivalents of p-tolyl 
thioester 108 in 1,2-dichloroethane at 50 °C for 24 hours. The double cross metathesis was found 
to be selective towards the E,E-dienes.23 This was clearly observed in the 1H NMR spectrums which 
showed coupling constants of J=14.4 Hz for 103 and J=15.5 Hz for 107 due to the 3J trans coupling 
of the alkene protons. The Cbz-amino thioester 103 was obtained in a much higher yield of 74% 
than the Boc-amino thioester 107 with a yield of 57%. Each metathesis reaction was run for 24 
hours and although we observed complete conversion of the starting material in both reactions (by 
TLC), the mass spectra for the Boc-amino thioester 107 showed the presence of the mono 
metathesis product. Running the reaction for 48 hours had little effect on the yield, so we surmised 
the that the catalyst was no longer active and increasing the catalyst loading may increase the yield 
of the desired product. With the cyclisation precursors successfully prepared our attention turned 
to the Brønsted acid catalyzed cyclisation reactions utilized in the “clip-cycle” methodology. 
 
 
   44 
 
9.3.  Brønsted Acid Catalyzed Cyclisation of Pyrrolizidine Precursors 
 
With the cyclisation precursors in hand and applying the optimized conditions established in the 
Clarke group,30 we advanced with the Brønsted acid catalyzed desymmetrisation cyclizations. These 
proceeded via an intramolecular aza-Michael reaction to generate the corresponding pyrrolidines 
racemically and asymmetrically. Firstly, each precursor was cyclized with racemic camphorsulfonic 
acid (CSA), in order to establish the HPLC conditions required to separate the two enantiomers of 
the major diastereomer. This would enable the determination of the enantiomeric excess (ee) 
obtained from each asymmetric cyclisation. Secondly, each precursor was cyclized asymmetrically 
using the chiral phosphoric acid catalyst (R)-TRIP. 
The Cbz-protected precursor 103 was investigated first. Precursor 103 was cyclised using 3 
equivalents of CSA in 1,2-dichloroethane at 50 °C for 24 hours (Scheme 31). Complete conversion 
to the corresponding racemic pyrrolidine 104 was observed and it was isolated in a good yield of 
75% for the major diastereomer. Pyrrolidine 104 is shown to have trans stereochemistry for the 
major diastereomer, although at this stage we did not know whether the major diastereomer was 
trans or cis. However, after the second cyclisation and NMR analysis of the resulting pyrrolizidine 
(as discussed in section 9.4), we could confirm that 104 formed with trans stereochemistry. 
 
Scheme 31. Racemic cyclisation of 103 using CSA 
 
The enantiomers were separated via chiral HPLC analysis using a CHIRALPAK IG column with a 
hexane/IPA (50:50) solvent system, at 25 °C and a flow rate of 0.7 ml/min. This gave good 
separation of the enantiomers with retention times of 52 min and 59 min and peak areas of 50.7% 
and 49.3% respectively, indicating a racemic mixture (Figure 12, Table 2). Small Peaks at 38 min and 
50 min were shown in the HPLC trace. These may have been due to small amounts of the minor 
diastereomer being present but this did not affect our ability to identify the retention times for the 
enantiomers of the major diastereomer. 
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1 52.762 50.7031 
2 59.259 49.2969 
Table 2. HPLC retention times and peak areas for the racemic Cbz-pyrrolidine 104 
 
Precursor 103 was then cyclized asymmetrically with (R)-TRIP (20 mol%) in cyclohexane at 80 °C for 
24 hours (Scheme 32). Under these conditions we achieved a 100% conversion to the 
corresponding Cbz-pyrrolidine 104, which was isolated in an excellent yield of 83%.  
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The enantiomers were again separated via chiral HPLC analysis using the same conditions as for the 
racemic cyclisation, CHIRALPAK IG column with a hexane/IPA (50:50) solvent system, at 25 °C and 
a flow rate of 0.7 ml/min. This gave retention times of 53 min for minor enantiomer and 59 min for 
the major enantiomer, with peak areas of 7.3% and 92.7% respectively, giving an enantiomeric 
excess of 85% (Figure 13, Table 3). The stereochemistry for pyrrolidine 104 can be assigned as the 
trans pyrrolidine with an (R,S) configuration for the major diastereomer, as shown in Scheme 32. 
The assignment is in line with the work conducted in the Clarke group for determining the 
stereochemistry of substituted pyrrolidines synthesized using the same CPA conditions, as 
previously discussed (Scheme 23 and Figure 10).30/37 
 
 








1 53.767 7.3342 
2 59.179 92.6658 
Table 3. HPLC retention times and peak areas for the chiral pyrrolidine 104 
 
NMR analysis was used to confirm the synthesis of pyrrolidine 104. The 1H NMR analysis was made 
more complicated due to the mixture of rotamers (1:1 ratio) observed in the spectrum, which were 
caused by the Cbz group. The assignment of the aromatics and the CH3 groups were 
straightforward. The aromatics gave a multiplet between 7.43 ppm and 7.18 ppm for 13 protons 
(H-1,2,3,9,10,24,25) and the CH3 groups gave a singlet at 2.37 ppm for 6 protons (H-7,27) (Figure 
14). The CH2 from the Cbz group could also be easily assigned as the multiplet between 5.30 ppm 
and 5.07 ppm (2 protons, H-5), since there was no coupling observed for this CH2 in the 2D COSY 
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spectrum (Figure 17). The other CH2 groups were assigned to the multiplets between 2.39 ppm and 
1.37 ppm for 8 protons (H-15,16,18,19), with the exception of the CH2 at H-21 which will be 
discussed later. 
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Figure 15. 1H NMR spectrum for pyrrolidine 104 showing the splitting for the alkene protons 
 
The alkene protons appeared as mix of rotamers in a 1:1 ratio (Figure 15). H-13 showed as two 
doublets at 6.22 ppm (H-13a) and 6.12 ppm (H-13b) each with a coupling constant of J=15.6 Hz, 
which is due to the 3J trans coupling with H-14. H-14 gave two doublet of triplets at 6.96 ppm (H-
14a) and 6.86 ppm (H-14b) with coupling constants of J=15.7 Hz for the 3J trans coupling to H-13, 
and J=6.6 Hz for the 3J coupling to H-15 (CH2). 
In order to assign the peaks between 3.36 ppm and 2.59 ppm (Figure 16), we needed to look at the 
quaternary carbons at each carbonyl C-6, C-12 and C-22. Each quaternary carbon produces two 
peaks close together in the 13C spectrum (due to rotamers) and a 2D HMBC spectrum was used to 
assign them (Figure 18). The peaks at 159.9 ppm and 156.1 ppm were assigned to C-6 as they 
correlate to the CH2 of the Cbz group (H-5). The peaks at 188.4 ppm and 188.6 ppm were assigned 
to C-12 as they correlate to the alkene protons H-13 and H-14. The peaks at 195.9 ppm and 196.1 
ppm can be assigned to C-22 and they correlate to the peaks between 3.36 ppm and 2.59 ppm in 
the 1H NMR spectrum, which can now be assigned to H-21 (CH2). As the H-21 protons are next to a 
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stereocentre they are nonequivalent and so generate double doublets, they are also shown in 
figure 16 as a mix of rotamers (1:1 ratio). One H-21 proton produces a double doublet at 3.36 ppm 
and 3.07 ppm (H-21a and H-21b) which have a 2J coupling constant of J=14.8 Hz (coupled to H-21) 
and a 3J coupling constant of J=3.2 Hz (coupled to H-20). The other H-21 proton produces a double 
doublet at 2.67 ppm and 2.59 ppm (H-21c and H-21d) which have a 2J coupling constant of J=15.0 
Hz (coupled to H-21) and a 3J coupling constant of J=9.8 Hz (coupled to H-20). From the 2D COSY 
spectrum (Figure 17), H-21 couples to the mutiplet between 4.37 ppm and 4.25 ppm which can 
now be assigned as H-20. By process of elimination the mutiplet between 3.91 ppm and 3.78 ppm 
must be assigned to H-17. 
 
Figure 16. 1H NMR spectrum for pyrrolidine 104 
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Figure 17.2D COSY spectrum for pyrrolidine 104  
 
 
Figure 18. 2D HMBC spectrum for pyrrolidine 104  
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Next, we investigated the cyclisation reactions for the Boc-protected precursor 107. Precursor 107 
was cyclised racemically using the same conditions, 3 equivalents of CSA in 1,2-dichloroethane at 
50 °C for 24 hours (Scheme 33). A 100% conversion of precursor 107 to the corresponding racemic 
Boc-pyrrolidine 115 was observed by TLC, however 115 was isolated in a much lower yield of 48% 
for the major diastereomer. We surmised that the acidic conditions of the reaction may have been 
strong enough to remove the Boc-protecting group, which would lead to further cyclisation to the 
pyrrolizidine. 
 
Scheme 33. Racemic cyclisation of 107 using CSA 
 
The enantiomers were separated via chiral HPLC analysis using a CHIRALPAK IG column with a 
hexane/IPA (90:10) solvent system, at 25 °C and a flow rate of 0.7 ml/min. This gave good 
separation of the enantiomers with retention times of 55 min and 59 min and peak areas of 49.4% 
and 50.6% respectively, indicating a racemic mixture (Figure 19, Table 4).  
 
 













1 55.117 49.4286 
2 59.991 50.5714 
Table 4. HPLC retention times and peak areas for the racemic pyrrolidine 115 
 
The racemic Boc-pyrrolidine 115 was not isolated cleanly from the flash column chromatography 
(Figure 20) and this would account for the number of small peaks that show up in the HPLC trace. 
However, these peaks did not affect our ability to identify the retention times for the enantiomers 
of the major diastereomer and show that 115 had been generated racemically. 
 
Figure 20. 1H NMR spectrum for the racemic pyrrolidine 115 
  
   53 
 
Precursor 107 was then cyclised asymmetrically with (R)-TRIP (20 mol%) in cyclohexane at 80 °C for 
24 hours (Scheme 34). 100% conversion to the corresponding chiral pyrrolidine 115 was achieved 
with a good yield of 79% for the major diastereomer. The enantiomers were again separated via 
chiral HPLC analysis using the same conditions as for the racemic cyclisation, CHIRALPAK IG column 
with a hexane/IPA (90:10) solvent system, at 25 °C and a flow rate of 0.7 ml/min. This gave retention 
times of 55 min for minor enantiomer and 59 min for the major enantiomer, with peak areas of 
8.6% and 91.4% respectively, giving an enantiomeric excess of 83% (Figure 21, Table 5).  
 
Scheme 34. Asymmetric cyclisation of 107 using (R)-TRIP 
 
 








1 55.404 8.5719 
2 59.744 91.4281 
Table 5. HPLC retention times and peak areas for asymmetric pyrrolidine 115 
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We were pleased to observe that the asymmetric cyclisations were consistent for both the Cbz and 
Boc precursors, with only a small reduction in yield and %ee for the Boc protected pyrrolidine 115. 
This showed that the protecting groups employed had little effect on the asymmetric cyclisation 
when using (R)-TRIP as the catalyst. The NMR analysis for the Boc-pyrrolidine was the same as for 
the Cbz-pyrrolidine with the exception of additional rotamers caused by the Boc group. The protons 
at each stereocenter (H-16 and H-19) now gave a mix of rotamers with a 1:1 ratio (Figure 22). The 
methyls from the Boc group also show as rotamers, generating two singlets at 1.48 ppm and 1.51 
ppm for the 9 protons. 
 
Figure 22. 1H NMR spectrum for pyrrolidine 115 
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9.4.  Cyclisation from the Pyrrolidine to the Pyrrolizidine 
 
With the asymmetric cyclisation to pyrrolidines 104 and 115 in high yields and ees accomplished, 
we turned our attention to the deprotection and subsequent intramolecular aza-Michael 
cyclisation to form the pyrrolizidine motif found in 3,5-disustituted pyrrolizidine alkaloids. We 
envisaged this could be achieved via a one-pot deprotection-cyclisation reaction. Since at this stage 
we did not know whether 104 had trans or cis stereochemistry, three possible diastereomers could 
be generated from the deprotection-cyclisation reaction (Figure 23). In relation to the bridgehead 
proton, two meso-pyrrolizidines 116 and 117 with cis-cis or trans-trans configurations and a chiral 
pyrrolizidine 118 with a trans-cis configuration are the possible diastereomers. In order to 
determine which of these pyrrolizidines is obtained from the deprotection-cyclisation we would 
need to analyze the relationship between the bridgehead proton and the protons at each 
stereocentre. 
 
Figure 23. Possible pyrrolizidine diastereomers 
 
The deprotection of the Cbz protecting group posed the greatest challenge as traditional methods 
of cleaving the Cbz group could not be used due to the functionality present in pyrrolidine 104. 
Hydrogenolysis with H2 over a palladium catalyst could also lead to competitive reduction of the 
alkene, which would prevent the desired intramolecular cyclisation to form the pyrrolizidine. In a 
similar fashion HBr could undergo electrophilic addition to the alkene.  
The strong Lewis acid boron trichloride (BCl3) has been shown to cleave the benzyl ether (OBn) 
protecting group45 and was successfully utilized within the Clarke group in the studies towards the 
synthesis of hexacyclinic acid.46 This was done in the presence of an alkene and ester functional 
groups. The benzyl ether protecting group is also more commonly removed using H2, Pd/C or HBr. 
We envisaged that BCl3 could be used in the same way to deprotect the Cbz group. Treating 
pyrrolidine 104 with a 1M solution of BCl3 in DCM was successful in cleaving the Cbz group. The 
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subsequent cyclisation to pyrrolizidine 116 was achieved with a yield of 38% and 116 was isolated 
as a single diastereomer (Scheme 35).  
 
Scheme 35. Cbz deprotection and cyclisation of pyrrolidine 116 using BCl3 
 
The 1H NMR spectrum for pyrrolizidine 116 (Figure 24) showed a quintet at 3.62 ppm for the 
bridgehead proton (H-11) and a multiplet at 3.27 ppm for the protons at each stereocentre (H-
8,14). This was comparable to the data reported by Stockman et. al.24 for the diethyl ester 
pyrrolizidine 55, with the bridgehead proton giving a quintet at 3.59 ppm and the protons at the 
stereocentres giving a multiplet at 3.18 ppm (Figure 25).  
 
Figure 24. 1H NMR spectrum for pyrrolizidine 116 
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Figure 25. Comparison of the diethyl ester pyrrolizidine 55 with pyrrolizidine 116 
 
Pyrrolizidine 116 also gave an [α]D reading of zero, therefore we initially assumed the 
stereochemistry to be that of the meso-pyrrolizidine with a cis-cis configuration. If this assumption 
was correct, it meant that the ee of pyrrolidine 104, achieved through the asymmetric cyclisation, 
was inconsequential when forming the meso-pyrrolizidine 116.   
Deprotecting the Boc-protected pyrrolidine 115 was more straightforward, as the Boc group can be 
easily removed using an acid. Pyrrolidine 115 was treated with 4M HCl in 1,4-dioxane under dry 
conditions. This also generated the same cis-cis pyrrolizidine 116 as a single diastereomer with a 
yield of 35% (Scheme 36). The 1H NMR spectrum for the Boc deprotection-cyclization matched with 
the 1H NMR spectrum for the Cbz deprotection-cyclisation, therefore the same pyrrolizidine 
diastereomer was forming in each case.  
  
Scheme 36. Boc deprotection and cyclisation of pyrrolidine 115 using 4M HCl in dioxane 
 
To confirm the stereochemistry of pyrrolizidine 116 we decided to synthesize the diethyl ester 
pyrrolizidine 55 and compare our data with that previously published in the literature. Three 
diastereomers for the diethyl ester pyrrolizidine have been reported (Figure 26). Stockman et. al.24 
reported the cis-cis pyrrolizidine 55 and Spring et. al.26 reported the trans-trans 67 and the trans-
cis 68 pyrrolizidines.  
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Figure 26. Reported diastereomers of the diethyl ester pyrrolizidine 
 
The diethyl ester pyrrolizidine was obtained via a two-step one-pot synthesis involving the 
treatment of pyrrolidine 115 with 4M HCl in 1,4-dioxane to form pyrrolizidine 116, followed by 
transesterification of the thioesters using a 1M solution of sodium ethoxide in EtOH (Scheme 37). 
The diethyl ester pyrrolizidine 55 was isolated as a single diastereomer with a good yield of 54%.  
 
Scheme 37. Boc deprotection and transesterification of pyrrolidine 115 
 
The 1H NMR data for the diethyl ester pyrrolizidine 55 was assigned as shown in Figure 27. The ethyl 
groups were assigned first, with H-1 and H-15 giving a triplet at 1.25 ppm with a 3J coupling constant 
of J=7.3 Hz for 6 protons, and H-2 and H-14 giving a quartet at 4.11 ppm with a 3J coupling constant 
of J=7.3 Hz for 4 protons. The multiplets at 1.45 ppm and 1.96 were assigned to the CH2 groups 
around the pyrrolizidine ring (H-6,7,9 and 10). The 2D COSY spectrum (Figure 28) shows that the 
single proton at 3.58 ppm couples to the CH2 groups to give a quintet with a 3J coupling constant of 
J=6.5 Hz, therefore this proton was assigned as the bridgehead proton H-8. The multiplet at 3.18 
ppm was assigned to the protons at each stereocenter, H-5 and H-11, as they couple to the CH2 
groups and the peaks at 2.24 ppm and 2.54 ppm. The remaining protons at H-4 and H-12 are 
assigned to the double doublets at 2.24 ppm and 2.54 ppm which have 3J coupling constants of 
J=15.0, 8.2 Hz and J=15.0, 6.0 Hz respectively. The splitting patern of H-4 and H-12 is due to the 
protons being nonequivalent as there is a stereocentre in the molecule.  
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Figure 27. 1H NMR spectrum for pyrrolizidine 55 
 
 
Figure 28. 2D COSY spectrum for pyrrolizidine 55 
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We then proceeded to compare our 1H and 13C NMR data with the data reported in the literature 
for the three possible pyrrolizidines (Table 6). Straight away we could rule out the chiral 
pyrrolizidine with the trans-cis configuration (highlighted orange), as there are significant 
differences between our data and the reported data. The three differences that stand out the most 
are shown in entries 4, 5 and 6. H-4 and H-12 give four double doublets in the 1H NMR and two 
peaks in the 13C NMR for the trans-cis pyrrolizidine, whereas our data gives two double doublets in 
the 1H NMR and one peak in the 13C NMR (Entry 4). The protons at the stereocenters (H-5 and H-
11) give a multiplet at 3.18 ppm in our 1H NMR data, but they are split into two peaks at 3.37 ppm 
(pentet) and 3.55 ppm (multiplet) for the trans-cis pyrrolizidine (Entry 5). H-6, 7, 9 and 10 give four 
multiplets and one triplet of doublet of doublets in the 1H NMR and four peaks in the 13C NMR for 
the trans-cis pyrrolizidine, whereas our data gives two multiplets in the 1H NMR and two peaks in 
the 13C NMR (Entry 6).  
The data comparison between our data and the two meso-pyrrolizidines (cis-cis and trans-trans) 
were very similar with only two minor differences (highlighted blue). The trans-trans pyrrolizidine 
gives a pentet for the protons at the stereocenters, H-5 and H-11, and a multiplet for the bridgehead 
proton H-8, whereas our data and the data for the cis-cis pyrrolizidine give a multiplet for H-5 and 
H-11 and a pentet for H-8. Although our data matches best with that of the cis-cis pyrrolizidine we 
cannot say for certain that we have not formed the trans-trans pyrrolizidine. In order to distinguish 
between the two meso-pyrrolizidines we ran a 2D NOSEY experiment to analyze the relationship 
between the bridgehead proton and the protons at the stereocenters. For the trans-trans 
pyrrolizidine we would expect to see through space interactions between these protons whereas 
the cis-cis pyrrolizidine would show no NOE interactions. The NOESY spectrum for pyrrolizidine 55 
(Figure 29) showed no NOE interactions between the bridgehead proton (H-8) and the protons at 
the stereocenters (H-5 and H-11), and so we are confident in reporting the stereochemistry of 
pyrrolizidine 55 as the meso-pyrrolizidine with a cis-cis configuration. 
 
   





























1 and 15 1.25 t 14.4 1.26 t 14.2 1.26 t 14.6 1.26 t 14.6 
2 








4 and 12 2.24 dd 
2.54 dd 
41.7 2.24 dd 
2.54 dd 






































8 3.58 p 64.5 3.59 p 64.3 3.59 m 64.8 3.65 m 66.5 
           *t - triplet, q - quartet, p - pentet, dd - double doublet, tdd – triplet of doublet of doublets and m - multiplet  
Table 6. 1H NMR and 13C NMR data comparison 
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9.5.  Selective Reduction of the Saturated Thioester 
 
With the synthesis of a pyrrolizidine successfully accomplished, we turned are attention to 
attempting to selectively reduce and functionalize the saturated thioester. This was to negate the 
problem of generating a meso-pyrrolizidine from a chiral starting material with a high ee and to 
install the functionality found in 3,5-disubstituted pyrrolizidine alkaloids. Once the saturated 
thioester had been functionalized (Scheme 38), we could proceed with the deprotection-cyclization 
which would generate an unsymmetrical chiral pyrrolizidine 120. The thioester on pyrrolizidine 120 
can then be functionalized to generate a 3,5-disubstituted pyrrolizidine alkaloid 121. For this part 
of the investigation, we decided that the Boc protected pyrrolidine 115 would be taken forward. 
This was to avoid the use of BCl3 due to its acute toxicity and the ease with which the Boc group 
can be removed.  
 
Scheme 38. Selective functionalization for the synthesis of pyrrolizidine alkaloids 
 
The challenge we were faced with for this functional group transformation was how to selectively 
reduce the saturated thioester in the presence of the unsaturated thioester. Work published by 
Fujioka et. al.47 presented us with a possible solution. Their work demonstrated the selective 
reduction of carbonyl functionalities in the presence of α,β-unsaturated ketones. The two-step 
procedure involved the in-situ protection of the enone using PPh3 and TMSOTf to form a 
phosphonium silyl enol ether. The other carbonyl functional group could then be treated with the 
desired nucleophile, and once the reaction was complete the temporary protection could be easily 
removed during work-up (Scheme 39). 
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Scheme 39. General scheme for the in-situ protection and reduction methodology reported by 
Fujioka et. al.47 
 
We attempted the reduction using 1.5 equivalents of PPh3 and TMSOTf in DCM at 0 °C, to form the 
in-situ protection, followed by 3 equivalents of DIBAL at -78 °C (Scheme 40).  Disappointingly, the 
mass spectra of the crude reaction material did not show the presence of aldehyde 122 and the 1H 
NMR spectrum showed no sign of an aldehyde peak in the 8-10 ppm region. We surmised that the 
in-situ protection was not occuring which may be due to the sterically hindered position of the 
enone in relation to the Boc group and the bulky PPh3. The enones utilized by Fujioka et. al. were 
all sterically unhindered. 
 
Scheme 40. Selective reduction of the saturated thioester to the aldehyde 
 
An alternative method was to use a palladium catalyzed cross-coupling reaction developed by 
Liebeskind and Srogl.48 The reaction involves a palladium catalyzed cross-coupling of a thioester 
with a boronic acid, mediated by a copper co-catalyst to generate the corresponding ketone 
(Scheme 41).  
 
Scheme 41. General scheme for the palladium catalysed cross-coupling reaction reported by 
Liebeskind and Srogl.48 
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The Liebeskind-Srogl reaction was successfully utilised in the Clarke group for the synthesis of 
diospongin A,49 where they used a procedure reported by Fuwa et. al.50 to convert the saturated 
thioester to an aryl ketone (Scheme 42).  
 
Scheme 42. Liebeskind-Srogl reaction utilised for the synthesis of diospongin A49 
 
Following the same procedure, we attempted to convert the saturated thioester to the aryl ketone. 
This was done using 10 mol% of tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3, 3 equivalents 
of copper(I) thiophene-2-carboxylate (CuTC) and 1 equivalent of phenylboronic acid. The starting 
material was consumed in 2.5 hours as shown by TLC (Scheme 43).   
 
Scheme 43. Liebeskind-Srogl cross-coupling reaction using phenylboronic acid 
 
Unfortunately, the reaction was not selective towards the saturated thioester, the mass spectra of 
the crude reaction material showed that the cross-coupling had taken place at the unsaturated 
thioester as well as the saturated thioester giving the double addition product 125. The mass 
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spectra also showed that we had formed a single addition product, which could be the 
functionalization of the saturated thioester 123 or the unsaturated thioester 124 or a mixture of 
both. Disappointingly, we were unable to separate the mixture of compounds by flash column 
chromatography. 
Unable to selectively functionalize the saturated thioester we turned our attention to the 
unsaturated thioester (Scheme 44). Oxidative cleavage of the alkene in 115 should lead to the 
aldehyde 126 which could then undergo intramolecular cyclisation on removal of the Boc group. 
This would generate the iminium ion intermediate 127 which could be treated with an appropriate 
nucleophile to install functionality at the 5 position on the pyrrolizidine ring 128.   
 
Scheme 44. Proposed oxidative cleavage of the unsaturated thioester 
 
Initially we performed the oxidative cleavage using the Lemieux-Johnson oxidation.51 Following a 
literature procedure,52 pyrrolidine 115 was treated with osmium tetroxide (0.5 mol%) and sodium 
metaperiodate (2 equiv) in a mixture of THF and water (2:1) for 1 hour (Scheme 45). Benzyl triethyl 
ammonium chloride (BTEAC) was added to aid the reaction in bi-phasic conditions.  
 
Scheme 45. Oxidative cleavage of 115 via a Lemieux-Johnson oxidation 
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The two step reaction proceeds via dihydroxylation of the alkene by osmium tetroxide to form the 
diol, followed by oxidative cleavage with sodium metaperiodate to form the aldehyde. Sodium 
metaperiodate also re-oxidises osmium tetroxide from Os(VI) to Os(VIII) and so the osmium 
tetroxide can be used in catalytic amounts. Although the reaction was successful, aldehyde 126 was 
isolated with a 27% yield.   
In an attempt to increase the yield of aldehyde 126 and avoid using the volatile and toxic osmium 
tetroxide, we decided to use an Upjohn dihydroxylation reaction53 to form the diol, before adding 
sodium metaperiodate to cleave the diol and form the aldehyde. Here osmium tetroxide is 
generated in-situ from potassium osmate by the oxidising agent N-methylmorpholine-N-oxide 
(NMO), which also re-oxidises osmium tetroxide from Os(VI) to Os(VIII). Following a literature 
procedure,54 pyrrolidine 115 was added to potassium osmate (10 mol%) and a stoichiometric 
quantity of NMO in a THF and water mixture (4:1) at room temperature. The reaction was followed 
by TLC and took 72 hours for the starting material to be consumed. Sodium metaperiodate (2 equiv) 
was then added and the reaction run for a further 72 hours at room temperature (Scheme 46). 
 
Scheme 46. Oxidative cleavage of 115 via an Upjohn dihydroxylation and sodium metaperiodate 
 
After 72 hours the reaction was stopped because the mass spectra of the crude reaction mixture 
showed that over oxidation of 126 to form the peroxyacid was occurring. Unfortunately, 
considering the long reaction time, aldehyde 126 was only isolated with a yield of 23%. 
Alternatively, the diol formed from the dihydroxylation step could be isolated and purified before 
being treated with sodium metaperiodate. Studies into the cyclisation of 126 will be the subject of 
future work. 
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9.6.  Synthesis of the Indolizidine precursor 
 
The two-directional asymmetric “clip-cycle” methodology employed herein for the synthesis of 
pyrrolizidines can be extended towards the synthesis of indolizidines. The strategy would involve 
using an unsymmetrical chiral precursor for the CPA catalyzed intramolecular aza-Michael 
cyclization to form the chiral pyrrolidine, which could then undergo further cyclization to the 
indolizidine. As the chiral precursor is racemic, kinetic resolution studies would need to be 
performed in order to generate an enantioenriched CPA cyclized product. Kinetic resolutions are 
dependent upon one enantiomer of the substrate reacting faster than the other and so as the 
reaction proceeds an enantiopure product is formed while the enantiomeric excess (ee) of the 
chiral precursor increases.55 Ideally running the reaction to 50% conversion will give an ee >99% for 
both the product and the recovered starting material, with a maximum yield of 50% (Figure 30).    
 
Figure 30. Catalytic kinetic resolution55 
 
The s-factor, which equates to the relative rate of reaction (krel), is a measure of the selectivity of 
the kinetic resolution, and is calculated by dividing the rate of reaction of the substrate enantiomer 
that reacts fast (kfast) by the rate of reaction of the substate enantiomer that reacts slow (kslow). A 
high s-factor is required to generate the product with a high ee. Another consideration that needs 
to be made is the potential of the unsymmetrical chiral precursor cyclizing to the piperidine as well 
as the pyrrolidine. According to Baldwin’s rules56 both the 5-exo-trig cyclization to form the 
pyrrolidine and the 6-exo-trig cyclisation to form the piperidine are favored. Although 5-membered 
rings are slightly less stable than 6-membered rings due to ring strain, we would expect the 5-
membered ring to form in preference to the 6-membered ring as a result of kinetic control. The 
activation energy barrier ΔG‡ (Gibbs free energy) for 5-membered rings is lower than the ΔG‡ for 6-
membered rings. This can be explained by the relation of ΔG‡ to the enthalpy of activation ΔH‡ and 
the entropy of activation ΔS‡ which is represented by the equation ΔG‡ = ΔH‡-TΔS‡. As there is a 
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small difference between the ΔH‡ value for 5 and 6 membered rings the important factor is the ΔS‡ 
value. There is more disorder in the chain that cyclizes to the 6-membered ring than the chain that 
cyclizes to the 5-membered ring and so the ΔS‡ is larger and negative for the formation of the 6-
membered ring leading to a larger ΔG‡. The 5-membered ring being the kinetic product will form 
faster than the 6-membered ring which would be the thermodynamic product.  
The forward synthesis for unsymmetrical chiral precursor required an extra step compared with 
that of the pyrrolizidine precursor, as 5-hexenal 130 was not commercially available (Scheme 47).  
 
Scheme 47. Synthesis of indolizidine cyclisation precursors 135a-b 
 
The synthesis began with a Swern oxidation converting primary alcohol 129 to aldehyde 130 
following a literature proceedure.57 The reaction proceeds via acylation between DMSO and oxalyl 
chloride to form a chlorosulfonium ion which then reacts with the alcohol. The resulting 
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alkoxysulfonium salt is deprotonated with Et3N to give a sulfur ylide which decomposes to give the 
aldehyde and dimethyl sulfide. Aldehyde 130 was obtained in a good yield of 88%. However 
because 130 was highly volatile it was kept in a solution of pentane/Et2O after flash column 
chromatography. The yield was calculated by determining the percentage by weight of the product 
and the solvents (Et2O and pentane) in the solution. This was achieved by inputting the peak 
integrations from the 1H NMR spectra into an NMR residual solvents calculator (Figure 31 and Table 
7). The percentage by weight calculated for the product could then be used to calculate the 
percentage yield (Figure 32). 
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Product Et2O Pentane 
Peak integration 1 3.76 3.88 
Protons in peak 1 4 6 
MW (g/mol) 98.15 74.12 72.15 
% by weight 46.16 31.90 21.94 
Table 7. NMR product and residual solvent percentages 
 
 
Figure 32. Yield calculation for aldehyde 130 
 
Next, the Grignard reaction between 4-butenyl magnesium bromide and aldehyde 130 generated 
chiral secondary alcohol 131 in a moderate yield of 53%. Converting 131 to the amine salt 132 was 
achieved through a Mitsunobu reaction using phthalimide as the N-nucleophile, followed by 
hydrazinolysis with hydrazine hydrate and an aqueous acid work-up. The amine salt 132 was 
obtained in an excellent yield of 94%. Amine salt 132 was then either Cbz protected with benzyl 
chloroformate or Boc protected with di-tert-butyl dicarbonate. Disappointingly the isolated yields 
for 134a and 134b were much lower, 34% and 49% respectively, compared to the symmetrical 
dienes 56 and 102. Finally protected amines 134a-b were “clipped” with p-tolyl thioester 108 via a 
two-directional double alkene cross-metathesis reaction using the optimised conditions. The 
metatheses were performed using Hoveyda-Grubbs catalyst™ 2nd generation (10 mol%) and CuI as 
a co-catalyst, with 6 equivalents of p-tolyl thioester 108 in 1,2-dichloroethane at 50 °C for 24 hours. 
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Both amino thioesters 135a and 135b were isolated in moderate yields of 64% and 60% 
respectively.  
Precursors 135a and 135b were then cyclized racemically using the optimized conditions of 3 
equivalents of CSA in 1,2-dichloroethane at 50 °C for 24 hours (Schemes 48 and 49). Complete 
conversion to the corresponding racemic pyrrolidines 136 and 137 was observed by TLC, but the 
isolated yields were significantly lower, 57% and 38% respectively, than compared to the racemic 
cyclisation of the symmetrical precursors 104 and 115. We surmised that this could be due to the 
formation of the six membered rings (piperidine) although they were not isolated from the crude 
reaction material. The 1H-NMR data for 136 and 137 was consistent with the 1H NMR data for the 
pyrrolidines generated from the desymmetrization cyclizations. The key peaks for the protons at 
each stereocentre resonate at 4.29 ppm (H-21) and 3.82 ppm (H-18) for 136 (Figure 33), which is 
consistent with the resonance of the same protons from the pyrrolidine formed from the 
desymmetrization (4.30 ppm and 3.85 ppm). The same is true for 137 (Figure 34). We are confident 
that the pyrrolidines have formed as the major product in each case.  
The next step would be to find HPLC conditions for the unsymmetrical precursors and the racemic 
pyrrolidines, which could then be used to conduct kinetic resolution studies on the asymmetric 
cyclizations. Unfortunately, due to time constraints caused by the COVID-19 pandemic, the kinetic 
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Figure 34. 1H NMR spectrum of racemic pyrrolidine 137 
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9.7.  Conclusion and Future Work 
 
The synthesis of the symmetrical and unsymmetrical linear cyclisation precursors (103,107 and 
135a-b) was achieved effectively using a two-directional approach over 5 steps and 6 steps 
respectively. The double alkene cross metathesis reactions, between the Cbz and Boc protected 
amino dienes and thioacrylate 108, catalyzed by Hoveyda-Grubbs catalyst™ 2nd generation gave 
good yields (57% - 74%) and selectivity towards the E,E-dienes. The yields for the Boc protected 
precursors were found to be lower in each case. The asymmetric cyclizations catalyzed by the chiral 
Brønsted acid catalyst (R)-TRIP generated chiral pyrrolidines 104 and 115 with high yields and ees 
for the major diastereomers. Only a slight reduction in yield and ee was observed for the Boc 
protected pyrrolidine compared to the Cbz protected pyrrolidine.  
Both the Cbz and Boc protected chiral pyrrolidines (104 and 115) were successfully deprotected 
and cyclized to form pyrrolizidine 55 as a single diastereomer. Confirmation of the absolute 
stereochemistry was determined by comparison of 1H NMR data published in the literature for 
stereoisomers of the 3,5-disutituted diethyl ester pyrrolizidine and 2D NOESY experiment. The 
stereochemistry was found to be that of the meso-pyrrolizidine with a cis-cis configuration. 
Unfortunately, the high ees obtained for pyrrolidines 104 and 115 via the asymmetric cyclisation 
reactions, were inconsequential when forming the meso-pyrrolizidine (116) in the second 
cyclisation. Initial attempts to selectively functionalize the saturated thioester present in the chiral 
pyrrolidine 115 met with failure. However, oxidative cleavage of the alkene contained in the 
unsaturated thioester to form aldehyde 126 were successful, although only with a low yield.  
In conclusion, coupling a two-directional approach with the “clip-cycle” methodology developed in 
the Clarke group for the synthesis of substituted chiral pyrrolidines, can be used to synthesize the 
pyrrolizidine motif found in natural alkaloids. Although this resulted in the meso-pyrrolizidine, 
further studies towards the selective functionalization of the saturated thioester could mitigate this 
problem and allow the chirality of the pyrrolidine obtained from the asymmetric cyclization to be 
retained.    
Future work would focus on the deprotection and cyclisation of aldehyde 126 obtained from the 
oxidative cleavage of pyrrolidine 115. This would generate an iminium ion intermediate which could 
then be treated with an appropriate nucleophile to install functionality at the 5 position on the 
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pyrrolizidine ring. For example, following the deprotection of pyrrolidine 115 the resulting iminium 
ion intermediate 138 could be treated with allyl trimethyl silane and titanium tetrachloride via a 
Sakurai reaction (Scheme 50). After determining the stereochemistry at the 5 position on the 
resulting pyrrolizidine 139, the saturated thioester could be functionalized via a Liebeskind-Srogl 
reaction and the alkene reduced by H2 over a palladium catalyst. 
 
Scheme 50. Plausible functionalization via a Sakurai reaction 
 
Aldehyde 126 could also be trapped with dinitrophenyl hydrazine (2,4-DNP) to form a hydrazone 
140 which may crystalize, allowing the absolute stereochemistry of the chiral pyrrolidine to be 
determined by X-ray crystallography (Scheme 51).  
 
Scheme 51. Conversion of 126 into a hydrazone 
 
Future work would also include kinetic resolution studies of the asymmetric CPA catalyzed 
cyclisation of the unsymmetrical chiral precursors, with the view to generating enantiopure chiral 
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pyrrolidines. The process would involve finding the HPLC conditions for a 50:50 mixture of the 
precursors and the racemic pyrrolidines, which can then be used to conduct kinetic resolutions for 
the asymmetric cyclizations. The resulting chiral pyrrolidines could then be deprotected and 
cyclized to the corresponding indolizidines (Scheme 52). Unlike with the pyrrolizidine the 
indolizidines formed cannot be meso compounds. Determination of the stereochemistry at the 5 
position would need to be done first, before attempting to functionalize either the saturated or 
unsaturated thioesters of the chiral precursors in order to synthesis 3,5-disustituted indolizidine 
alkaloids. 
 
Scheme 52. Deprotection-cyclisation to form an indolizidine 
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10.  Experimental 
10.1.  General Experimental 
 
Unless otherwise noted all compounds were bought from commercial suppliers and used without 
further purification. Nuclear magnetic resonance spectra were recorded on a Jeol ECS-400 
spectrometer at ambient temperature; chemical shifts are quoted in parts per million (ppm) and 
were referenced as follows: chloroform-d, 7.26 ppm for 1H NMR; chloroform-d, 77.00 ppm for 13C 
NMR. Coupling constants (J) are quoted in Hertz. Infra-red spectra were recorded on an ATI Mattson 
Genesis FT-IR spectrometer. Mass spectrometry was performed by the University of York mass 
spectrometry service using electron spray ionization (ESI) and atmospheric-pressure chemical 
ionization (APCI) techniques. Optical rotations were carried out using a Billingham and Stanley 
ADP450 polarimeter and [α]D values are given in 10-1 deg.cm2.g-1. Thin layer chromatography was 
performed on aluminium sheets coated with Merck Silica gel 60 F254 or neutral aluminium oxide 60 
F254. The plates were developed using ultraviolet light, basic aqueous potassium permanganate or 
acidic aqueous ceric ammonium molybdate. Liquid chromatography was performed using forced 
flow (flash column) with the solvent systems indicated. The stationary phase was silica gel 60 (220–
240 mesh) supplied by Sigma-Aldrich or neutral aluminium oxide 60 (40-300 μm) supplied by Acros. 
Dry solvents were acquired from PureSolv alumina columns from Innovative Technologies. High 
Performance Liquid Chromatography (HPLC) was performed using an Agilent 1200 series 
instrument using the chiral columns indicated and a range of wavelengths from 210-280 nm for 
detection. All other solvents and reagents were used as received from commercial suppliers. All 
numbering on the structures below is for the benefit of characterization and does not necessarily 
conform to IUPAC rules. 
  
   79 
 
10.2.  Experimental Procedures 
 
 
S-p-tolyl prop-2-enethioate (108) 
Sodium borohydride (0.05 g, 1.32 mmol) and p-thiocresol (5.46 g, 44.0 mmol) were added to a 
solution of NaOH (15% w/w aq. 20 ml) and the resulting solution was stirred at room temperature 
for 1 hour to form the sodium salt of p-thiocresol (p-CH3C6H4S-Na+). In a separate flask, BHT (0.136 
g, 0.616 mmol) and acryloyl chloride (5.97 g, 66.0 mmol) were dissolved in cyclohexane (40 ml). 
Both solutions were ice-cooled before use. The p-CH3C6H4S-Na+ solution was then added over 10 
mins to the solution of acryloyl chloride and the resulting mixture was stirred at 55 °C for 35 mins. 
The reaction was cooled to room temperature and extracted with diethyl ether (100 ml). The 
organic layer was washed with 5% aqueous NaHCO3 solution and brine, dried over Na2SO4 and 
concentrated in vacuo (a portion of BHT (0.136 g) was added to the filtrate to prevent 
polymerization during the evaporation of the solvent). The crude product was purified by flash 
column chromatography (SiO2, 2% Et2O/hexane) to afford 108 as a colourless oil (4.18 g, 23.0 mmol, 
53% yield). TLC (SiO2) Rf = 0.29 (5% Et2O/hexane). 1H NMR (400 MHz, CDCl3); δ 7.32 (2 H, d, J = 7.9 
Hz, H-5), 7.24 (2 H, d, J = 7.9 Hz, H-6), 6.44 (1 H, dd, J = 17.2, 9.5 Hz, H-2), 6.37 (1 H, dd, J = 17.2, 1.7 
Hz, H-1), 5.75 (1 H, dd, J = 9.5, 1.7 Hz, H-1), 2.38 (3 H, s, H-8) ppm; 13C NMR (101 MHz, CDCl3); δ 
189.1 (C-3), 139.9 (C-7), 134.7 (C-5), 134.5 (C-2), 130.2(C-6), 127.4 (C-1), 123.7 (C-4), 21.5 (C-8) ppm; 
IR (ATR): νmax 3024, 2922, 1682, 1612, 1494, 1447, 1394, 1304, 1210, 1160, 1117, 987, 941, 807, 









Magnesium turnings (1.22 g, 50.0 mmol) and iodine (1 crystal) were added to a flame dried flask 
under N2, which was warmed until the iodine sublimed. The flask was allowed to cool to room 
temperature before the addition of dry THF (40 ml). To this mixture, 4-bromo-1-butene (5.08 ml, 
50.0 mmol) was added slowly at room temperature (the flask was placed in a water bath to control 
the temperature). The resulting reaction mixture was then stirred at room temperature for 1 h to 
form the Grignard reagent. The reaction was then cooled to 0 °C before the addition of ethyl 
formate (1.62 ml, 20.0 mmol) in dry THF (10 ml) over 10 mins. The reaction mixture was then stirred 
at room temperature overnight. The reaction mixture was cooled to 0 °C and quenched with 
saturated NH4Cl solution (50 ml). The aqueous phase was then extracted with Et2O (3 x 50ml). The 
combined organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by flash column chromatography (SiO2, 5% EtOAc/hexane) to afford 
secondary alcohol 100 as a yellow oil (2.42 g, 17.3 mmol, 86% yield). Data was consistent with those 
reported in the literature.40  TLC (SiO2) Rf = 0.19 (10% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 
5.84 (2H, ddt, J = 16.9, 10.1, 6.8 Hz, H-2,8), 5.05 (2H, ddd, J = 17.3, 3.6, 1.4 Hz, H-1,9), 4.97 (2H, dd, 
J = 10.1, 1.4 Hz, H-1,9), 3.69 – 3.61 (1H, m, H-5), 2.27 – 2.07 (4H, m, CH2), 1.63 – 1.47 (5H, m, CH2 
and OH) ppm; 13C NMR (101 MHz, CDCl3); δ 138.7 (C-2,8), 114.9 (C-1,9), 71.1 (C-5), 36.6 (C-4,6), 30.2 
(C-3,7) ppm; IR (ATR): νmax 3342, 3078, 2978, 2933, 1641, 1449, 1416, 1314, 1079, 992, 908, 639, 




Phthalimide (1.44 g, 9.80 mmol) and triphenylphosphine (2.57 g, 9.80 mmol) were dissolved in THF 
(50 ml). Secondary alcohol 100 (1.10 g, 7.84 mmol) was then added followed by DEAD (5 ml, 11.0 
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mmol) at room temperature over 20 min. The reaction mixture was stirred at room temperature 
for 24 h. The solvent was then removed under reduced pressure and the resulting crude oil 
triturated with hexane/Et2O (2:1 mixture) until complete removal of the solids. The combined 
organic layers were concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, 2% EtOAc/pentane) to afford N-alkyl phthalimide 113 as a colourless oil 
(1.23 g, 4.56 mmol, 58% yield). TLC (SiO2) Rf = 0.29 (5% EtOAc/pentane). 1H NMR (400 MHz, CDCl3); 
δ 7.82 (2H, dd, J = 5.5, 3.2 Hz, H-2), 7.71 (2H, dd, J = 5.5, 3.1 Hz, H-1), 5.75 (2H, ddt, J = 17.0, 10.1, 
6.7 Hz, H-6,12), 4.96 (2H, ddd, J = 17.0, 3.3, 1.4 Hz, H-5,13), 4.90 (2H, dd, J = 10.1, 1.4, Hz, H-5,13), 
4.23 (1H, m, H-9), 2.28 – 2.17 (2H, m, CH2), 2.10 – 1.95 (4H, m, CH2), 1.85 – 1.75 (2H, m, CH2) ppm; 
13C NMR (101 MHz, CDCl3); δ 168.9 (C-4), 137.6 (C-6,12), 134.0 (C-1), 131.9 (C-3), 123.3 (C-2), 115.3 
(C-5,13), 51.4 (C-9), 31.7 (C-8,10), 31.0 (C-7,11) ppm; IR (ATR): νmax 3078, 2929, 1772, 1704, 1641, 
1613, 1468, 1453, 1393, 1368, 1334, 1172, 1068, 992, 911, 880, 794, 719, 699, 641, 609, 550, 531, 
510, cm-1; HRMS (APCI) 270.1479 (M + H+. C17H20NO2 requires 270.1489). 
 
 
Benzyl nona-1,8-dien-5-ylcarbamate (102) 
Phthalimide 113 (2.00 g, 7.46 mmol) was dissolved in EtOH (70 ml). Hydrazine hydrate (1.08 ml, 
22.28 mmol) was then added and the reaction mixture was refluxed overnight, during this time a 
white solid precipitated. The reaction was cooled to room temperature and quenched with 
concentrated HCl (37% w/w, 28ml). The solvent was removed under reduced pressure and the 
residual aqueous solution was diluted with H2O (80 ml) and then washed with Et2O (3 x 80ml). The 
aqueous layer was treated with NaOH until pH 12 and then extracted with Et2O (3 x 80ml). The 
combined organic layers were washed with 2M HCl (aq, 5 x 80 ml). The aqueous layer was 
concentrated in vacuo to give the amine HCl salt 114 (1.18 g, 6.72 mmol, 90% yield). To the amine 
HCl salt 114 (188 mg, 1.07 mmol) was added K2CO3 (50% w/w, aq, 0.37 ml, 2.67 mmol) and 1,4-
dioxane (5 ml) and the resulting mixture was stirred for 15 min to generate the free amine. Benzyl 
chloroformate (0.18 ml, 1.28 mmol) was then added. The reaction mixture was stirred at room 
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temperature for 5 h. The reaction was quenched with H2O (5 ml) and extracted with DCM (3 x 10ml). 
The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. 
The crude product was purified by flash column chromatography (SiO2, 10% EtOAc/hexane) to 
afford Cbz-Amine 102 as a white solid (237 mg, 0.87 mmol, 81% yield). TLC (SiO2) Rf = 0.21 (10% 
EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 7.41 – 7.28 (5H, m), 5.81 (2H, ddt, J = 17.2, 10.1, 6.6 
Hz, H-8,14), 5.09 (2H, s, H-5), 5.01 (2H, bd, J = 17.2 Hz, H-7,15), 4.96 (2H, bd, J = 10.1 Hz, H-7,15), 
4.52 (1H, d, J = 9.2 Hz, H-NH), 3.75 – 3.58 (1H, m, H-11), 2.18 – 2.02 (4H, m, CH2), 1.64 – 1.55 (2H, 
m, CH2), 1.53 – 1.42 (2H, m, CH2) ppm; 13C NMR (101 MHz, CDCl3); δ 156.2 (C-6), 138.1 (C-8,14), 
136.8 (C-4), 128.7 (C-1/2/3), 128.2 (C-1/2/3), 115.1 (C-7,15), 66.7 (C-5), 50.8 (C-11), 34.8 (C-10,12), 
30.2 (C-9,13) ppm; IR (ATR): νmax 3321, 3075, 2935, 2852, 1692, 1640, 1532, 1452, 1415, 1330, 1230, 
1243, 1215, 1046, 1028, 994, 910, 774, 736, 696, 642, 458, cm-1; HRMS (ESI) 296.1616 (M + Na+. 
C17H23NNaO2 requires 296.1621). 
 
 
tert-butyl nona-1,8-dien-5-ylcarbamate (56) 
Phthalimide 113 (2.00 g, 7.46 mmol) was dissolved in EtOH (70 ml). Hydrazine hydrate (1.08 ml, 
22.28 mmol) was then added and the reaction mixture was refluxed overnight, during this time a 
white solid precipitated. The reaction was cooled to room temperature and quenched with 
concentrated HCl (37% w/w, 28ml). The solvent was removed under reduced pressure and the 
residual aqueous solution was diluted with H2O (80 ml) and then washed with Et2O (3 x 80ml). The 
aqueous layer was treated with NaOH until pH 12 and then extracted with Et2O (3 x 80ml). The 
combined organic layers were washed with 2M HCl (aq, 5 x 80 ml). The aqueous layer was 
concentrated in vacuo to give the amine HCl salt 114 (1.18 g, 6.72 mmol, 90% yield). To a solution 
of amine HCl salt 114 (500 mg, 2.85 mmol) and di-tert-butyl dicarbonate (747 mg, 3.42 mmol) in 
THF (12 ml) at 0 °C was added Et3N (1.00 ml, 7.13 mmol) in THF (7 ml) over 10 min. The reaction 
mixture was allowed to warm to room temperature before being heated at 40 °C for 2 h. The 
reaction was cooled to room temperature and the salts removed by filtration before being 
concentrated in vacuo. The residue was dissolved in DCM (40 ml) and washed with a saturated 
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solution NH4Cl (aq), a saturated solution NaHCO3 (aq) and brine. The organic layer was dried over 
Na2SO4 and concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, 10% Et2O/hexane) to afford Boc-amine 56 as a white solid (492 mg, 1.93 
mmol, 68% yield). Data was consistent with those reported in the literature.40 TLC (SiO2) Rf = 0.33 
(20% Et2O/hexane). 1H NMR (400 MHz, CDCl3); δ 5.81 (2H, ddt, J = 16.8, 10.1, 6.5 Hz, H-7,13), 5.01 
(2H, ddd, J = 17.1, 3.3, 1.3 Hz, H-6,14), 4.95 (2H, dd, J = 10.1, 1.9 Hz, H-6,14), 4.27 (1H, bd, J = 9.5 
Hz, H-NH), 3.66 – 3.53 (1H, m, H-10), 2.18 – 2.01 (4H, m, CH2), 1.62 – 1.52 (2H, m, CH2), 1.48 – 1.39 
(2H, m, CH2), 1.43 (9H, s, H-1,2,3) ppm; 13C NMR (101 MHz, CDCl3); δ 155.7 (C-5), 138.3 (C-7,13), 
114.9 (C-6,14), 79.0 (C-4), 50.0 (C-10), 34.9 (C-9,11), 30.3 (C-8,12), 28.5 (C-1,2,3) ppm; IR (ATR): νmax 
3336, 3078, 2978, 2931, 2859, 1684, 1641, 1524, 1451, 1391, 1366, 1301, 1247, 1172, 1046, 1024, 
993, 909, 874, 777, 640, cm-1; HRMS (ESI) 262.1778 (M + Na+. C14H25NNaO2 requires 262.1777). 
 
 
(2E,9E)-S,S-di-p-tolyl 6-(((benzyloxy)carbonyl)amino)undeca-2,9-dienebis(thioate) (103)  
Thioester 108 (587 mg, 3.29 mmol) was dissolved in 1,2-DCE (10 ml) and placed under N2. Cbz-
amine 102 (150 mg, 0.549 mmol) was dissolved in 1,2-DCE (10 ml) and placed under N2. To a flame 
dried flask under N2 were added Hoveyda-Grubbs Catalyst™ 2nd generation (34.0 mg, 0.0549 
mmol) and copper iodide (105 mg, 0.549 mmol), followed by the solutions of thioester and Cbz-
amine. The flask was then degassed and backfilled with N2 (x3). The reaction mixture was heated 
to 50 °C for 24 h. The reaction was then cooled to room temperature and concentrated in vacuo. 
The crude product was purified by flash column chromatography (SiO2, 10%-50% EtOAc/hexane) to 
afford amino-thioester 103 as a brown oil (235 mg, 0.409 mmol, 74% yield). TLC (SiO2) Rf = 0.13 
(20% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 7.38 – 7.28 (9H, m, H-1,2,3,10,24), 7.21 (4H, d, J 
= 8.1 Hz, H-9,25), 6.93 (2H, dt, J = 15.6, 6.9 Hz, H-14,20), 6.18 (2H, bd, J = 15.5 Hz, H-13,21), 5.20 – 
5.00 (2H, m, H-5), 4.53 (1H, d, J = 9.5 Hz, H-NH), 3.75 – 3.62 (1H, m, H-17), 2.37 (6H, s, H-7,27), 2.35 
   84 
 
– 2.20 (4H, m, CH2), 1.74 – 1.63 (2H, m, CH2), 1.59 – 1.48 (2H, m, CH2) ppm; 13C NMR (101 MHz, 
CDCl3) δ 188.6 (C-12/22), 156.2 (C-6), 145.1 (C-14,20), 139.8 (C-8,26), 134.7 (C-10,24), 130.1 (C-
9,25), 128.7/128.4 (C-1,2,3), 128.3 (C-13,21), 124.1 (C-11,23), 67.1 (C-5), 51.0 (C-17), 34.1 (C-16,18), 
29.0 (C-15,19), 21.5 (C-7,27) ppm; IR (ATR): νmax 3347, 3031, 2922, 2859, 1682, 1630, 1525, 1494, 
1449, 1400, 1337, 1287, 1236, 1181, 1141, 1090, 1053, 1017, 974, 807, 736, 698, 649, 536, 475 cm-
1; HRMS (ESI) 596.1890 (M + Na+. C33H35NNaO4S2 requires 596.1900). 
 
 
(2E,9E)-S,S-di-p-tolyl 6-((tert-butoxycarbonyl)amino)undeca-2,9-dienebis(thioate) (107)  
Thioester 108 (684 mg, 3.89 mmol) was dissolved in 1,2-DCE (10 ml) and placed under N2. Boc-
amine 56 (150 mg, 0.549 mmol) was dissolved in 1,2-DCE (10 ml) and placed under N2. To a flame 
dried flask under N2 were added Hoveyda-Grubbs Catalyst™ 2nd generation (40.1 mg, 0.0639 
mmol) and copper iodide (122 mg, 0.639 mmol), followed by the solutions of thioester and Boc-
amine. The flask was then degassed and backfilled with N2 (x3). The reaction mixture was heated 
to 50 °C for 24 h. The reaction was then cooled to room temperature and concentrated in vacuo. 
The crude product was purified by flash column chromatography (SiO2, 10%-50% EtOAc/hexane) to 
afford amino-thioester 107 as a brown oil (198 mg, 0.367 mmol, 57% yield). TLC (SiO2) Rf = 0.18 
(20% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 7.31 (4H, d, J = 8.0 Hz, H-9,23), 7.21 (4H, d, J = 
7.9 Hz, H-8,24), 6.95 (2H, dt, J = 15.5, 6.9 Hz, H-13,19), 6.19 (2H, dd, J = 15.6, 1.6 Hz, H-12,20), 4.28 
(1H, d, J = 9.6 Hz, H-NH), 3.69 – 3.56 (1H, m, H-16), 2.38 (6H, s, H-6,26), 2.35 – 2.25 (4H, m, CH2), 
1.73 – 1.62 (2H, m, CH2), 1.59 – 1.51 (2H, m, CH2), 1.46 (9H, s, H-1,2,3) ppm; 13C NMR (101 MHz, 
CDCl3) δ 188.6 (C-11,21), 155.7 (C-5), 145.4 (C-13,19), 139.8 (C-7,25), 134.7 (C-9,23), 130.2 (C-8,24), 
128.3 (C-12,20), 124.1 (C-10,22), 79.7 (C-4), 50.4 (C-16), 34.3 (C-15,17), 29.1 (C-14,18), 28.5 (C-
1,2,3), 21.5 (C-6,26) ppm; IR (ATR): νmax 3374, 2976, 2924, 1710, 1683, 1631, 1598, 1514, 1494, 
1449, 1391, 1365, 1288, 1245, 1169, 1091, 1052, 1017, 975, 935, 863, 807, 705, 648, 618, 536, 475 
cm-1; HRMS (ESI) 562.2065 (M + Na+. C30H37NNaO4S2 requires 562.2056). 





For the racemic cyclisation, amino-thioester 103 (16.0 mg, 0.028 mmol) dissolved in 1,2-DCE (1.4 
ml) was added to racemic CSA (20.0 mg, 0.084 mmol) under N2. The reaction mixture was the 
heated to 50 °C for 24 h. The reaction was cooled to room temperature, quenched with Et3N (0.15 
ml), diluted with DCM (10 ml) and then washed with saturated NaHCO3. The organic layer was dried 
over Na2SO4 and concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, 10% EtOAc/hexane) to afford Cbz-pyrrolidine 104 as a colourless oil (12.3 
mg, 0.021 mmol, 75% yield). 
For the asymmetric cyclisation, amino-thioester 103 (89.0 mg, 0.155 mmol) dissolved in 
cyclohexane (10 ml) was added to (R)-TRIP (23.3 mg, 0.031 mmol) under N2. The reaction mixture 
was the heated to 80 °C for 24 h. The reaction was cooled to room temperature, quenched with 
Et3N (0.6 ml) and then concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, 5%-10% EtOAc/hexane) to afford Cbz-pyrrolidine 104 as a colourless oil 
(86.8 mg, 0.151 mmol, 97% yield (73.2 mg, 0.128 mmol, 83% yield, 86% ee, major diastereomer)) 
as a 1:1 mixture of rotamers. TLC (SiO2) Rf = 0.22 (20% EtOAc/hexane).1H NMR (400 MHz, CDCl3); δ 
7.43 – 7.18 (13H, m, H-1,2,3,9,10,24,25), 6.96 (1H, dt, J = 15.7, 6.6 Hz, H-14, rotamer 1), 6.86 (1H, 
dt, J = 15.7, 6.6 Hz, H-14, rotamer 2), 6.22 (1H, d, J = 15.6 Hz, H-13, rotamer 1), 6.12 (1H, d, J = 15.6 
Hz, H-13, rotamer 2), 5.30 – 5.07 (2H, m, H-5), 4.37 – 4.25 (1H, m, H-20), 3.91 – 3.78 (1H, m, H-17), 
3.36 (1H, dd, , J = 14.8, 3.2 Hz, H-21, rotamer 1), 3.07 (1H, dd, , J = 14.8, 3.2 Hz, H-21, rotamer 2), 
2.67 (1H, dd, , J = 15.0, 9.8 Hz, H-21, rotamer 1), 2.59 (1H, dd, , J = 15.0, 9.8 Hz, H-21, rotamer 2), 
2.37 (6H, s, H-7,27), 2.29 – 1.75 (6H, m, CH2), 1.73 – 1.64 (1H, m, CH2), 1.51 – 1.37 (1H, m, CH2) ppm; 
13C NMR (101 MHz, CDCl3) δ 196.1/195.9 (C-22), 188.6/188.4 (C-12), 154.1/153.9 (C-6), 145.4/145.1 
(C-14), 140.0/139.9/139.8/139.7 (C-8,26), 136.7/136.6 (C-4), 134.7/134.5/134.4 (C-10,24), 
130.2/130.1/130.1 (C-9,25), 128.7/128.7/128.3/128.3 (C-1,2,3), 128.2 (C-13), 
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124.2/124.1/124.0/123.9 (C-11,23), 67.0 (C-5), 57.9/57.3 (C-17), 55.2/54.7 (C-20), 47.2/45.7 (C-21), 
32.2/31.0 (C-16), 29.5/29.4 (C-15), 28.4/27.5 (C-19), 27.4/26.6 (C-18), 21.5 (C-7,27) ppm; IR (ATR): 
νmax 2923, 1692, 1631, 1598, 1494, 1453, 1404, 1354, 1330, 1305, 1211, 1182, 1103, 1061, 1017, 
989, 807, 771, 734, 698, 604, 534, 474 cm-1; HRMS (ESI) 596.1915 (M + Na+. C33H35NNaO4S2 requires 





For the racemic cyclisation, amino-thioester 107 (50.0 mg, 0.093 mmol) dissolved in 1,2-DCE (10 
ml) was added to racemic CSA (65.0 mg, 0.28 mmol) under N2. The reaction mixture was the heated 
to 50 °C for 24 h. The reaction was cooled to room temperature, quenched with Et3N (0.5 ml), 
diluted with DCM (10 ml) and then washed with saturated NaHCO3. The organic layer was dried 
over Na2SO4 and concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, 10% EtOAc/hexane) to afford Boc-pyrrolidine 115 as a yellow oil (24.2 mg, 
0.045 mmol, 48% yield). 
For the asymmetric cyclisation, amino-thioester 107 (56.0 mg, 0.104 mmol) dissolved in 
cyclohexane (5 ml) was added to (R)-TRIP (15.8 mg, 0.021 mmol) under N2. The reaction mixture 
was the heated to 80 °C for 24 h. The reaction was cooled to room temperature, quenched with 
Et3N (0.5 ml) and then concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, 5%-10% EtOAc/hexane) to afford Boc-pyrrolidine 115 as a yellow oil (52.9 
mg, 0.098 mmol, 94% yield (44.5 mg, 0.082 mmol, 79% yield, 84% ee, major diastereomer)) as a 1:1 
mixture of rotamers. TLC (SiO2) Rf = 0.30 (20% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 7.33 – 
7.26 (4H, m, H-9,23), 7.25 – 7.19 (4H, m, H-8,24), 7.01 – 6.89 (1H, m, H-13), 6.21 (1H, d, J = 15.8 Hz, 
H-12, rotamer 1), 6.17 (1H, d, J = 15.8 Hz, H-12, rotamer 2), 4.31 – 4.23 (1H, m, H-19, rotamer 1), 
4.21 – 4.14 (1H, m, H-19, rotamer 2), 3.84 – 3.77 (1H, m, H-16, rotamer 1), 3.75 – 3.68 (1H, m, H-
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16, rotamer 2), 3.33 (1H, dd, , J = 14.7, 3.2 Hz, H-20, rotamer 1), 3.11 (1H, dd, , J = 14.7, 3.2 Hz, H-
20, rotamer 2), 2.66 (1H, dd, , J = 14.6, 9.6 Hz, H-20, rotamer 1), 2.62 (1H, dd, , J = 14.6, 9.6 Hz, H-
20, rotamer 2), 2.37 (6H, s, H-6,26), 2.30 – 1.80 (6H, m, CH2), 1.70 – 1.63 (1H, m, CH2), 1.51 (9H, s, 
H-1,2,3, rotamer 1), 1.48 (9H, s, H-1,2,3, rotamer 2), 1.46 – 1.35 (1H, m, CH2) ppm; 13C NMR (101 
MHz, CDCl3) δ 196.1/196.0 (C-21), 188.6/188.5 (C-11), 153.6/153.5 (C-5), 145.6/145.4 (C-13), 
140.0/139.9/139.8/139.7 (C-7,25), 134.8/134.7/134.5/134.4 (C-9,23), 130.2/130.2/130.2/130.1 (C-
8,24), 128.4/128.2 (C-12), 124.3/124.2/124.0/123.9 (C-10,22), 80.2/79.9 (C-4), 57.5/57.1 (C-16), 
54.9/54.8 (C-19), 47.4/45.9 (C-20), 32.3/31.2 (C-15), 29.9/29.7 (C-14), 28.7 (C-1,2,3), 28.2/27.4 (C-
18), 27.4/26.6 (C-17), 21.5 (C-6,26) ppm; IR (ATR): νmax 2971, 2926, 1685, 1632, 1598, 1494, 1477, 
1454, 1386, 1365, 1305, 1277, 1256, 1167, 1119, 1104, 1016, 991, 887, 807, 774, 732, 647, 608, 
575, 534, 474 cm-1; HRMS (ESI) 562.2061 (M + Na+. C30H37NNaO4S2 requires 562.2056); [α]D20 -16.2 
(c 0.95, CHCl3) 
 
 
S,S'-di-p-tolyl 2,2'-((3R,5S,7as)-hexahydro-1H-pyrrolizine-3,5-diyl)diethanethioate (116) 
Cbz-pyrrolidine 104 (37.0 mg, 0.064 mmol) was dissolved in DCM (4 ml), 1M solution of boron 
trichloride in DCM (0.322 ml, 0.322 mmol) was then added at 0 °C and the reaction stirred at room 
temperature for 24 h. The reaction mixture was diluted with DCM (5 ml) and quenched with a 
saturated aqueous solution of NaHCO3. The organic layer was washed with brine, dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, 1:1 Et2O/hexane, column deadened with 1% Et3N) to afford pyrrolizidine 
116 as a colourless oil (10.5 mg, 0.024 mmol, 38% yield). 
Boc-pyrrolidine 115 (50.0 mg, 0.093 mmol) was dissolved in a 4M solution of HCl in dioxane (1 ml) 
and then stirred at room temperature for 24 h. The reaction mixture was diluted with DCM (2 ml) 
and quenched with solid K2CO3. The reaction was then washed with brine and extracted with DCM 
(3 x 5 ml). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
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The crude product was purified by flash column chromatography (SiO2, 1:1 Et2O/hexane, column 
deadened with 1% Et3N) to afford pyrrolizidine 116 as a colourless oil (14.5 mg, 0.033 mmol, 35% 
yield). TLC (SiO2) Rf = 0.32 (1:1 Et2O/hexane, plates deadened with 1% Et3N). 1H NMR (400 MHz, 
CDCl3); δ 7.31 – 7.27 (4H, m, H-4,18), 7.21 (4H, d, J = 8.1 Hz, H-3,19), 3.62 (1H, quintet, J = 6.7 Hz, 
H-11), 3.31 – 3.23 (2H, m, H-8,14), 2.90 (2H, dd, J = 14.9, 6.0 Hz, H-7,15), 2.60 (2H, dd, J = 14.7, 7.9 
Hz, H-7,15), 2.37 (6H, s, H-1,21), 2.06 – 1.91 (4H, m, CH2), 1.60 – 1.49 (2H, m, CH2), 1.49 – 1.38 (2H, 
m, CH2) ppm; 13C NMR (101 MHz, CDCl3) δ 196.8 (C-6,16), 139.7 (C-2,20), 134.6 (C-4,18), 130.2 (C-3,19), 
124.5 (C-5,17), 64.5 (C-11), 63.5 (C-8,14), 50.5 (C-7,15), 31.4 (C-CH2), 31.2 (C-CH2), 30.5 (C-CH2), 21.48 (C-1,21) 
ppm; IR (ATR): νmax 2954, 1700, 1598, 1494, 1400, 1354, 1182, 1088, 985, 807, 751, 534, 473 cm-1; 
HRMS (ESI) 462.1535 (M + Na+. C25H29NNaO2S2 requires 462.1532) 
 
 
Diethyl 2,2'-((3R,5S,7as)-hexahydro-1H-pyrrolizine-3,5-diyl)diacetate (55) 
Boc-pyrrolidine 115 (83.6 mg, 0.155 mmol) was dissolved in a 4M solution of HCl in dioxane (1 ml) 
and then stirred at room temperature for 24 h. The reaction mixture was concentrated in vacuo, 
dissolved in EtOH (1 ml), and then treated with 1M solution of NaOEt (3 equiv) for 24 h. The reaction 
was filtered and concentrated in vacuo. The crude residue was then dissolved in EtOAc, washed 
with a saturated aqueous solution of K2CO3 and the aqueous layer extracted with EtOAc (3 x 10 ml). 
The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography (Al2O3, 20% EtOAc/hexane) to afford 
pyrrolizidine 55 as a yellow oil (23.6 mg, 0.083 mmol, 54% yield). Data was consistent with those 
reported in the literature.24 TLC (Al2O3) Rf = 0.35 (20% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 
4.11 (4H, q, J = 7.3 Hz, H-2,14), 3.58 (1H, quintet, J = 6.5 Hz, H-8), 3.23 – 3.14 (2H, m, H-5,11), 2.54 
(2H, dd, J = 15.0, 6.0 Hz, H-4,12), 2.24 (2H, dd, J = 15.0, 8.2 Hz, H-4,12), 2.05 – 1.89 (4H, m, CH2), 
1.53 – 1.37 (4H, m, CH2), 1.25 (6H, t, J = 7.3 Hz, H-1,15) ppm; 13C NMR (101 MHz, CDCl3) δ 172.5 (C-
3,13), 64.5 (C-8), 63.0 (C-5,11), 60.3 (C-2,14), 41.7 (C-4,12), 31.5 (C-6,10), 31.2 (C-7,9), 14.4 (C-1,15) ppm; IR 
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(ATR): νmax 2919, 2850, 1731, 1464, 1448, 1417, 1370, 1296, 1268, 1250, 1170, 1141, 1105, 1086, 




(2S,5S)-tert-butyl 2-(2-oxo-2-(p-tolylthio)ethyl)-5-(3-oxopropyl)pyrrolidine-1-carboxylate (126) 
Boc-pyrrolidine 115 (20.0 mg, 0.037 mmol), osmium tetroxide (0.05 mg, 0.00019 mmol) and benzyl 
triethyl ammonium chloride (0.27 mg, 0.0012 mmol) were dissolved in THF and H2O (1.5 ml, 2:1). 
Sodium metaperiodate (16.0 mg, 0.074 mmol) was added and the resulting mixture stirred 
vigorously at room temperature for 1 h. The reaction was then diluted with H2O (5 ml) and extracted 
with DCM (3 x 5 ml). The combined organic layers were washed with brine, dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, 30% EtOAc/hexane) to afford aldehyde 126 as a yellow oil (3.96 mg, 0.010 
mmol, 27% yield). 
Boc-pyrrolidine 115 (120 mg, 0.22 mmol) was added to a stirred solution of potassium osmate (8.1 
mg, 0.022 mmol) and NMO (51.5 mg, 0.44 mmol) in THF and H2O (10 ml, 4:1). The reaction was 
stirred vigorously for 72 h, after which Sodium metaperiodate (94.1 mg, 0.44 mmol) was added and 
the resulting mixture stirred vigorously at room temperature for further 72 h. The reaction was 
then quenched with sodium metabisulfite solution (10 ml, 10% w/w aq) and extracted with EtOAc 
(3 x 10 ml). The combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography (SiO2, 30% 
EtOAc/hexane) to afford aldehyde 126 as a yellow oil (20.2 mg, 0.052 mmol, 23% yield) as a 1:1 
mixture of rotamers. TLC (SiO2) Rf = 0.36 (40% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 9.76 
(1H, s, H-6), 7.29 – 7.19 (4H, m, H-17,18), 4.30 – 4.23 (1H, m, H-13, rotamer 1), 4.20 – 4.13 (1H, m, 
H-13, rotamer 2), 3.84 – 3.77 (1H, m, H-10, rotamer 1), 3.75 – 3.68 (1H, m, H-10, rotamer 2), 3.33 
(1H, dd, , J = 14.7, 3.2 Hz, H-14, rotamer 1), 3.11 (1H, dd, , J = 14.7, 3.2 Hz, H-14, rotamer 2), 2.66 
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(1H, dd, , J = 14.8, 9.6 Hz, H-14, rotamer 1), 2.58 (1H, dd, , J = 14.8, 9.6 Hz, H-14, rotamer 2), 2.53 – 
2.38 (2H, m, H-CH2), 2.37 (3H, s, H-20), 2.20 – 1.82 (4H, m, CH2), 1.71 – 1.60 (2H, m, CH2), 1.50 (9H, 
s, H-1,2,3, rotamer 1), 1.48 (9H, s, H-1,2,3, rotamer 2), ppm; 13C NMR (101 MHz, CDCl3) δ 
202.1/201.6 (C-7), 196.1/196.0 (C-15), 153.6 (C-5), 140.0/139.8 (C-19), 134.6/134.5 (C-17), 
130.3/130.2 (C-18), 124.0 (C-16), 80.3/80.1 (C-4), 57.2 (C-10), 55.0/54.9 (C-13), 47.3/45.9 (C-14), 
41.4/41.2 (C-9), 29.9 (C-8), 28.7 (C-1,2,3), 28.2/27.5 (C-12), 27.5/26.8 (C-11), 21.5 (C-20) ppm; IR 
(ATR): νmax 2933, 1691, 1494, 1455, 1389, 1367, 1256, 1171, 1122, 1103, 996, 889, 808, 775, 721, 




Oxalyl chloride (2.90 ml, 34.3 mmol) was dissolved in DCM (50 ml), DMSO (4.70 ml, 66.2 mmol) was 
then added dropwise within 5 min at -78 °C. The reaction mixture was stirred at -78 °C for 10 min 
before 5-hexen-1-ol (2.50 ml, 20.8 mmol) in DCM (7.5 ml) was added dropwise over 10 min. The 
resulting reaction mixture was stirred at -78 °C for 1 h. Triethylamine (9.20 ml, 66.0 mmol) was 
added over 10 min and the reaction mixture allowed to warm to 0 °C, after which H2O (60 ml) and 
DCM (60 ml) were added and the phases separated. The aqueous phase was then extracted with 
DCM (3 x 60ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in 
vacuo (up to 500 mbar). The crude product was purified by flash column chromatography (SiO2, 
pentane/Et2O 9/1) to afford aldehyde 130 as a pale-yellow solution (1.80 g, 18.0 mmol, 88% yield) 
(aldehyde kept in a solution of pentane/Et2O due to volatility. Yield calculated from NMR). 
Magnesium turnings (446 mg, 18.3 mmol) and iodine (1 crystal) were added to a flame dried flask 
under N2, which was warmed until the iodine sublimed. The flask was allowed to cool to room 
temperature before the addition of dry THF (50 ml). To this mixture, 4-bromo-1-butene (1.86 ml, 
18.3 mmol) was added slowly at room temperature (the flask was placed in a water bath to control 
the temperature). The resulting reaction mixture was then stirred at room temperature for 1 h to 
form the Grignard reagent. The reaction was then cooled to 0 °C before the dropwise addition of 
aldehyde 130 (900 mg, 9.17 mmol) over 10 min. The reaction was stirred at room temperature 
overnight. The reaction mixture was then cooled to 0 °C and quenched with saturated aqueous 
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solution of NH4Cl (50 ml). The aqueous phase was extracted with Et2O (3 x 50ml) and the combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (SiO2, 10% EtOAc/hexane) to afford secondary alcohol 
131 as a yellow oil (746.1 mg, 4.84 mmol, 53% yield). Data was consistent with those reported in 
the literature.26 TLC (SiO2) Rf = 0.16 (10% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 5.83 (2H, ddt, 
J = 16.9, 10.4, 6.6 Hz, H-2,9), 5.80 (2H, ddt, J = 16.9, 10.1, 6.6 Hz, H-2,9), 5.08 – 4.92 (2H, m, H-1,10), 
3.67 – 3.58 (1H, m, H-5), 2.26 – 2.00 (4H, m, CH2), 1.62 – 1.38 (7H, m, CH2 and OH) ppm; 13C NMR 
(101 MHz, CDCl3); δ 138.8/138.7 (C-2,9), 114.9/114.8 (C-1,10), 71.5 (C-5), 37.0/36.6 (C-4,6), 
33.8/30.2 (C-3,8), 25.0 (C-7) ppm; IR (ATR): νmax 3343, 3078, 2978, 2931, 2860, 1641, 1441, 1416, 
1262, 993, 908, 827, 636, 554 cm-1; HRMS (APCI) 155.1436 (M + H+. C10H19O requires 155.1430). 
 
 
2-(deca-1,9-dien-5-yl)isoindoline-1,3-dione (132)  
Phthalimide (596 mg, 4.05 mmol) and triphenylphosphine (1.06 g, 4.05 mmol) were dissolved in 
THF (25 ml). Secondary alcohol 131 (500 mg, 3.24 mmol) was then added followed by DEAD (2.06 
ml, 4.54 mmol) at room temperature over 20 min. The reaction mixture was stirred at room 
temperature for 24 h. The solvent was then removed under reduced pressure and the resulting 
crude oil triturated with hexane/Et2O (2:1 mixture) until complete removal of the solids. The 
combined organic layers were concentrated in vacuo. The crude product was purified by flash 
column chromatography (SiO2, 5% EtOAc/hexane) to afford N-alkyl phthalimide 132 as a yellow oil 
(525 mg, 1.85 mmol, 57% yield). TLC (SiO2) Rf = 0.33 (10% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); 
δ 7.81 (2H, dd, J = 5.5, 3.2 Hz, H-2), 7.71 (2H, dd, J = 5.5, 3.2 Hz, H-1), 5.75 (1H, ddt, J = 17.0, 10.2, 
6.5 Hz, H-6,13), 5.72 (1H, ddt, J = 17.0, 10.2, 6.5 Hz, H-6,13) 5.00 – 4.87 (4H, m, H-5,14), 4.22 (1H, 
m, H-9), 2.28 – 1.97 (6H, m, CH2), 1.84 – 1.66 (2H, m, CH2), 1.42 – 1.26 (2H, m, CH2) ppm; 13C NMR 
(101 MHz, CDCl3); δ 168.9 (C-4), 138.4/137.6 (C-6,13), 134.0 (C-1), 131.9 (C-3), 123.3 (C-2), 
115.3/114.9 (C-5,14), 51.8 (C-9), 33.4/31.9 (C-8,10), 31.7/31.0 (C-7,12), 26.0 (C-11) ppm; IR (ATR): 
νmax 3077, 2928, 2860, 1772, 1704, 1641, 1613, 1468, 1456, 1393, 1369, 1332, 1261, 1172, 1068, 
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Benzyl deca-1,9-dien-5-ylcarbamate (134a)  
Phthalimide 132 (362 mg, 1.28 mmol) was dissolved in EtOH (20 ml). Hydrazine hydrate (0.12 ml, 
2.56 mmol) was then added and the reaction mixture was refluxed overnight, during this time a 
white solid precipitated. The reaction was cooled to room temperature and quenched with 
concentrated HCl (37% w/w, 5ml). The solvent was removed under reduced pressure and the 
residual aqueous solution was diluted with H2O (30 ml) and then washed with Et2O (3 x 30ml). The 
aqueous layer was treated with NaOH until pH 12 and then extracted with Et2O (3 x 30ml). The 
combined organic layers were washed with 2M HCl (aq, 5 x 30 ml). The aqueous layer was 
concentrated in vacuo to give the amine HCl salt 133 (230 g, 1.21 mmol, 94% yield). To the amine 
HCl salt 133 (50.8 mg, 0.268 mmol) was added K2CO3 (50% w/w, aq, 0.127 ml, 0.670 mmol) and 1,4-
dioxane (2 ml) and the resulting mixture was stirred for 15 min to generate the free amine. Benzyl 
chloroformate (0.050 ml, 0.32 mmol) was then added. The reaction mixture was stirred at room 
temperature for 5 h. The reaction was quenched with H2O (5 ml) and extracted with DCM (3 x 5 
ml). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in 
vacuo. The crude product was purified by flash column chromatography (SiO2, 10% EtOAc/hexane) 
to afford Cbz-Amine 134a as a white solid (26.2 mg, 0.0911 mmol, 34% yield). TLC (SiO2) Rf = 0.25 
(10% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 7.38 – 7.28 (5H, m, H-1,2,3), 5.86 – 5.70 (2H, m, 
H-8,15), 5.09 (2H, s, H-5) 5.05 – 4.91 (4H, m, H-7,16), 4.49 (1H, bd, J = 9.6 Hz, H-NH), 3.72 – 3.59 
(1H, m, H-11), 2.16 – 1.97 (4H, m, CH2), 1.62 – 1.30 (6H, m, CH2) ppm; 13C NMR (101 MHz, CDCl3); δ 
156.2 (C-6), 138.6/138.2 (C-8,15), 136.8 (C-4), 128.7/128.2 (C-1,2,3), 115.0/114.9 (C-7,16), 66.7 (C-
5), 51.0 (C-11), 34.9/34.8 (C-10,12), 33.6/30.25 (C-9,14), 25.16 (C-13) ppm; IR (ATR): νmax 3323, 
3074, 2935, 2857, 1693, 1641, 1532, 1455, 1415, 1243, 1053, 1028, 995, 910, 774, 736, 697, 642 
cm-1; HRMS (ESI) 310.1778 (M + Na+. C18H25NNaO2 requires 310.1777) 
   93 
 
 
tert-butyl deca-1,9-dien-5-ylcarbamate (134b) 
Phthalimide 132 (362 mg, 1.28 mmol) was dissolved in EtOH (20 ml). Hydrazine hydrate (0.12 ml, 
2.56 mmol) was then added and the reaction mixture was refluxed overnight, during this time a 
white solid precipitated. The reaction was cooled to room temperature and quenched with 
concentrated HCl (37% w/w, 5ml). The solvent was removed under reduced pressure and the 
residual aqueous solution was diluted with H2O (30 ml) and then washed with Et2O (3 x 30ml). The 
aqueous layer was treated with NaOH until pH 12 and then extracted with Et2O (3 x 30ml). The 
combined organic layers were washed with 2M HCl (aq, 5 x 30 ml). The aqueous layer was 
concentrated in vacuo to give the amine HCl salt 133 (230 g, 1.21 mmol, 94% yield). Amine HCl salt 
133 (230 mg, 1.21 mmol) and Et3N were added to DCM (10 ml) and stirred for 15 min to generate 
free amine. The reaction was then cooled to 0 °C before the addition of Di-tert-butyl dicarbonate 
(528 mg, 2.42 mmol). The reaction was stirred at room temperature for 24 h. The reaction was 
quenched with citric acid (0.1M aq. 15 ml) and extracted with DCM (3 x 30 ml). The combined 
organic layers were washed with a saturated solution NaHCO3 (aq) and brine, dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, 5% Et2O/hexane) to afford Boc-Amine 134b as a yellow oil (152 mg, 0.60 
mmol, 49% yield). Data was consistent with those reported in the literature.26 TLC (SiO2) Rf = 0.25 
(10% Et2O/hexane). 1H NMR (400 MHz, CDCl3); δ 5.87 – 5.73 (2H, m, H-7,14), 5.05 – 4.91 (4H, m, H-
6,15), 4.27 (1H, bd, J = 9.6 Hz, H-NH), 3.66 – 3.49 (1H, m, H-10), 2.19 – 1.96 (4H, m, CH2), 1.60 – 1.27 
(6H, m, CH2), 1.44 (9H, s, H-1,2,3) ppm; 13C NMR (101 MHz, CDCl3); δ 155.8 (C-5), 138.8/138.4 (C-
7,14), 114.9/114.8 (C-6,15), 79.1 (C-4), 50.2 (C-10), 35.1/35.0 (C-9,11), 33.7/30.4 (C-8,13), 28.6 (C-
1,2,3), 25.2 (C-12) ppm; IR (ATR): νmax 3342, 3078, 2978, 2932, 2858, 1687, 1641, 1519, 1453, 1391, 
1365, 1247, 1171, 1050, 995, 909, 864, 777, 641 cm-1; HRMS (ESI) 276.1934 (M + Na+. C15H27NNaO2 
requires 276.1934) 
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(2E,10E)-S,S-di-p-tolyl 6-(((benzyloxy)carbonyl)amino)dodeca-2,10-dienebis(thioate) (135a) 
Thioester 108 (93.0 mg, 0.522 mmol) was dissolved in 1,2-DCE (2.5 ml) and placed under N2. Cbz-
Amine 134a (25.0 mg, 0.087 mmol) was dissolved in 1,2-DCE (2.5 ml) and placed under N2. To a 
flame dried flask under N2 were added Hoveyda-Grubbs Catalyst™ 2nd generation (5 mg, 0.009 
mmol) and copper iodide (16 mg, 0.087 mmol), followed by the solutions of thioester and Cbz-
Amine. The flask was then degassed and backfilled with N2 (x3). The reaction mixture was then 
heated to 50 °C for 24 h. The reaction was then cooled to room temperature and concentrated in 
vacuo. The crude product was purified by flash column chromatography (SiO2, 10%-50% 
EtOAc/hexane) to afford amino-thioester 135a as a brown oil (33 mg, 0.056 mmol, 64% yield). TLC 
(SiO2) Rf = 0.15 (20% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 7.39 – 7.28 (9H, m, H-1,2,3,10,25), 
7.22 (4H, dd, J = 8.1, 2.4 Hz, H-9,26), 7.00 – 6.86 (2H, m, H-14,21), 6.18 (2H, bd, J = 14.4 Hz, H-13,22), 
5.20 – 5.03 (2H, m, H-5), 4.47 (1H, d, J = 9.5 Hz, H-N-H), 3.75 – 3.62 (1H, m, H-17), 2.38 (6H, s, H-
7,28), 2.35 – 2.14 (4H, m, CH2), 1.75 – 1.35 (6H, m, CH2) ppm; 13C NMR (101 MHz, CDCl3) δ 
188.7/188.6 (C-12,23), 156.2 (C-6), 145.8/145.3 (C-14,21), 139.8 (C-8,27), 134.7 (C-10,25), 130.1 (C-
9,26), 128.7 (C-1,2,3), 128.3/128.3 (C-13/22), 124.1 (C-11,24), 67.0 (C-5), 51.0 (C-17), 35.3 (C-
16/18), 34.2 (C-16,18), 32.1/29.1 (C-15,20), 24.5 (C-19), 21.5 (C-7,28) ppm; IR (ATR): νmax 3346, 
3030, 2925, 2859, 1683, 1630, 1524, 1494, 1452, 1399, 1237, 1055, 1017, 807, 738, 698, 649, 535, 
475 cm-1; HRMS (ESI) 610.2056 (M + Na+. C34H37NNaO4S2 requires 610.2056). 
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(2E,10E)-S,S-di-p-tolyl 6-((tert-butoxycarbonyl)amino)dodeca-2,10-dienebis(thioate) (135b) 
Thioester 108 (422 mg, 2.37 mmol) was dissolved in 1,2-DCE (9 ml) and placed under N2. Boc-amine 
134b (100 mg, 0.395 mmol) was dissolved in 1,2-DCE (9 ml) and placed under N2. To a flame dried 
flask under N2 were added Hoveyda-Grubbs Catalyst™ 2nd generation (25.0 mg, 0.0395 mmol) and 
copper iodide (75.0 mg, 0.395 mmol), followed by the solutions of thioester and Boc-amine. The 
flask was then degassed and backfilled with N2 (x3). The reaction mixture was heated to 50 °C for 
24 h. The reaction was then cooled to room temperature and concentrated in vacuo. The crude 
product was purified by flash column chromatography (SiO2, 10%-30% EtOAc/hexane) to afford 
amino-thioester 135b as a brown oil (131.8 mg, 0.238 mmol, 60% yield). TLC (SiO2) Rf = 0.19 (20% 
EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 7.31 (4H, dd, J = 8.2, 1.6 Hz, H-9,24), 7.22 (4H, d, J = 
8.2 Hz, H-8,25), 7.00 – 6.89 (2H, m, H-13,20), 6.19 (2H, dd, J = 15.5, 2.5 Hz, H-12,21), 4.26 (1H, d, J 
= 9.6 Hz, H-NH), 3.68 – 3.54 (1H, m, H-16), 2.38 (6H, s, H-6,27), 2.35 – 2.18 (4H, m, H-14,19), 1.73 – 
1.48 (6H, m, H-15,17,18), 1.46 (9H, s, H-1,2,3) ppm; 13C NMR (101 MHz, CDCl3) δ 188.7/188.6 (C-
11,22), 155.8 (C-5), 145.9/145.6 (C-13,20), 139.8 (C-7,26), 134.7 (C-9,24), 130.1 (C-8,25), 
128.3/128.2 (C-12,21), 124.1 (C-10,23), 79.5 (C-4), 50.2 (C-16), 35.4/34.3 (C-15,17), 32.1,29.1 (C-
14,19), 28.5 (C-1,2,3), 24.5 (C-18), 21.5 (C-6,26) ppm; IR (ATR): νmax 3368, 2975, 2928, 2863, 1681, 
1630, 1598, 1511, 1494, 1450, 1391, 1365, 1303, 1245, 1167, 1105, 1092, 1053, 1017, 982, 807, 









For the racemic cyclisation, amino-thioester 135a (30.0 mg, 0.051 mmol) dissolved in 1,2-DCE (2.5 
ml) was added to racemic CSA (36.0 mg, 0.153 mmol) under N2. The reaction mixture was the 
heated to 50 °C for 24 h. The reaction was cooled to room temperature, quenched with Et3N (0.3 
ml), diluted with DCM (10 ml) and then washed with saturated aqueous solution of NaHCO3. The 
organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (SiO2, 10%-20% EtOAc/hexane) to afford Cbz-pyrrolidine 
136 as a colourless oil (17.3 mg, 0.029 mmol, 57% yield) for the major diastereomer with as a 1:1 
mixture of rotamers. TLC (SiO2) Rf = 0.21 (20% EtOAc/hexane).1H NMR (400 MHz, CDCl3); δ 7.44 – 
7.19 (13H, m, H-1,2,3,9,10,25,26), 6.94 (1H, dt, J = 15.6, 6.5 Hz, H-14, rotamer 1), 6.91 (1H, dt, J = 
15.6, 6.5 Hz, H-14, rotamer 2), 6.17 (1H, d, J = 15.6 Hz, H-13, rotamer 1), 6.11 (1H, d, J = 15.6 Hz, H-
13, rotamer 2), 5.24 – 5.08 (2H, m, H-5), 4.35 – 4.25 (1H, m, H-21), 3.88 – 3.76 (1H, m, H-18), 3.37 
(1H, dd, J = 14.8, 3.2 Hz, H-22, rotamer 1), 3.07 (1H, dd,  J = 14.8, 3.2 Hz, H-22, rotamer 2), 2.67 (1H, 
dd, J = 14.9, 9.8 Hz, H-22, rotamer 1), 2.59 (1H, dd,  J = 14.9, 9.8 Hz, H-22, rotamer 2), 2.37 (6H, s, 
H-7,28), 2.35 – 1.81 (6H, m, CH2), 1.73 – 1.62 (1H, m, CH2), 1.53 – 1.27 (3H, m, CH2) ppm; 13C NMR 
(101 MHz, CDCl3) δ 196.1/195.9 (C-23), 188.7/188.5 (C-12), 154.2/153.9 (C-6), 146.1/145.8 (C-14), 
140.0/139.8/139.8/139.7 (C-8,27), 136.8/136.7 (C-4), 134.7/134.7/134.5/134.5 (C-10,25), 
130.2/130.1 (C-9,26), 128.7/128.7/128.2/128.2 (C-1,2,3), 128.1 (C-13), 124.1/124.0/123.9 (C-
11,24), 66.7 (C-5), 58.2/57.7 (C-18), 55.1/54.6 (C-21), 47.2/45.8 (C-22), 33.8 (C-15) 32.5/32.3/32.1 
(C-16), 28.4/27.6 (C-20), 27.5/26.5 (C-19), 25.2/25.1 (C-17), 21.5 (C-7,28) ppm; IR (ATR): νmax 2923, 
1689, 1631, 1494, 1454, 1404, 1353, 1330, 1305, 1281, 1211, 1181, 1103, 1017, 985, 806, 771, 733, 
698, 648, 603, 534, 474 cm-1; HRMS (ESI) 610.2064 (M + Na+. C34H37NNaO4S2 requires 610.2056). 
 





For the racemic cyclisation, amino-thioester 135b (53.0 mg, 0.096 mmol) dissolved in 1,2-DCE (5 
ml) was added to racemic CSA (67.0 mg, 0.288 mmol) under N2. The reaction mixture was the 
heated to 50 °C for 24 h. The reaction was cooled to room temperature, quenched with Et3N (0.5 
ml), diluted with DCM (10 ml) and then washed with saturated aqueous solution of NaHCO3. The 
organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (SiO2, 10% EtOAc/hexane) to afford Boc-pyrrolidine 137 
as a yellow oil (20.6 mg, 0.036 mmol, 38% yield) for the major diastereomer with as a 1:1 mixture 
of rotamers. TLC (SiO2) Rf = 0.29 (20% EtOAc/hexane). 1H NMR (400 MHz, CDCl3); δ 7.33 – 7.26 (4H, 
m, H-9,24), 7.25 – 7.18 (4H, m, H-8,25), 6.94 (1H, dt, J = 14.6, 9.6 Hz, H-13), 6.19 (1H, d, J = 15.5 Hz, 
H-12, rotamer 1), 6.16 (1H, d, J = 15.5 Hz, H-12, rotamer 2), 4.30 – 4.21 (1H, m, H-20, rotamer 1), 
4.20 – 4.12 (1H, m, H-20, rotamer 2), 3.81 – 3.73 (1H, m, H-17, rotamer 1), 3.72 – 3.64 (1H, m, H-
17, rotamer 2), 3.33 (1H, dd, J = 14.7, 3.2 Hz, H-21, rotamer 1), 3.11 (1H, dd, J = 14.7, 3.2 Hz, H-21, 
rotamer 2), 2.65 (1H, dd, J = 14.8, 9.7 Hz, H-21, rotamer 1), 2.58 (1H, dd, J = 14.8, 9.7 Hz, H-21, 
rotamer 2), 2.37 (6H, s, H-6,27), 2.34 – 1.80 (6H, m, CH2), 1.69 – 1.60 (2H, m, CH2), 1.51 (9H, s, H-
1,2,3, rotamer 1), 1.48 (9H, s, H-1,2,3, rotamer 2), 1.46 – 1.36 (2H, m, CH2) ppm; 13C NMR (101 MHz, 
CDCl3) δ 196.2/196.1 (C-22), 188.7/188.5 (C-11), 153.7/153.5 (C-5), 146.3/145.9 (C-13), 
140.0/139.8/139.8/139.7 (C-7,26), 134.7/134.5/134.5 (C-9,24), 130.2/130.1 (C-8,25), 
128.3/128.2/128.0/127.9 (C-12), 124.3/124.2/124.0 (C-10,23), 80.0/79.7 (C-4), 57.7/57.6 (C-17), 
54.8/54.7 (C-20), 47.4/47.3/46.0/45.9 (C-21), 33.8 (C-14), 32.6/32.3 (C-15), 28.7 (C-1,2,3), 28.2/27.5 
(C-19), 27.5/26.5 (C-18), 25.3/25.2 (C-16), 21.5 (C-6,27) ppm; IR (ATR): νmax 2972, 2924, 1685, 1632, 
1598, 1494, 1454, 1387, 1365, 1257, 1168, 1117, 1017, 987, 911, 889, 806, 773, 731, 647, 608, 573, 
534, 474 cm-1; HRMS (ESI) 576.2213 (M + Na+. C31H39NNaO4S2 requires 576.2213). 
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11.  Abbreviations 
 
(R)-anth-cat (R)-3,3’-Bis(9-anthracenyl)-1,1’-binaphthyl-2,2’-diyl hydrogenphosphate 
(R)-phen-cat (11bR)-2,6-Di-9-phenanthrenyl-4-hydroxy-dinaphtho[2,1-d:1’,2’-
f][1,3,2]dioxaphosphepin-4-oxide 
(R)-TiPSY (R)-3,3’-Bis(triphenylsilyl)-1,1’-binaphthyl-2,2’-diyl hydrogenphosphate  
(R)-TRIP (R)-3,3’-Bis(2,4,6-triisopropylphenyl)-1,1’-binaphthyl-2,2’-diyl hydrogenphosphate 
1,2-DCE  1,2-dichloroethane 
1,2-DME 1,2-dimethoxyethane  
4 Å M S  4 Ångström molecular sieves 
aq  aqueous 
APCI  atmospheric pressure chemical ionization 
BHT   butylated hydroxy toluene (2,6-di-t-butyl-4-methylphenol) 
Boc  tert-butyloxycarbonyl 
BTEAC  benzyl triethyl ammonium chloride 
cat.  catalyst 
Cbz  carboxybenzyl 
COSY  correlated spectroscopy 
CPA  chiral phosphoric acid 
CSA   camphorsulfonic acid 
CuTC  copper(I)-thiophene-2-carboxylate 
DEAD  diethyl azodicarboxylate 
DIBAL  diisobutylaluminium hydride 
DMF  N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
dr   diastereomic ratio 
ee  enantiomeric excess 
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eq.  equivalents 
ESI   electrospray ionization  
FDA  U.S. Food and Drug Administration 
HMBC  heteronuclear multiple bond coherence 
HPLC  High Performance Liquid Chromatography 
IR  infra-red 
J  coupling constant (Hz) 
LDA  lithium diisopropylamide  
NMO  N-methylmorpholine N-oxide 
NMR  nuclear magnetic resonance 
NOESY  nuclear overhauser effect 
OTf  trifluoromethanesulfonate 
Py  pyridine 
rt  room temperature 
t-Bu  tert-butyl 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
TLC   thin layer chromatography 
TMS  trimethylsilyl 
Ts  p-toluenesulfonyl  
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